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Numerous epidemiological studies associate chronic inhalation of metal mixtures with increased 
risk of pulmonary diseases.  Although exposure to metal mixtures is of great public health 
relevance, the integration of cellular responses to metals within these mixtures that promote 
disease is poorly understood.  This dissertation investigated the hypothesis that chromium (VI) 
(Cr(VI)) stimulates signaling that alters transcriptional complexes to silence protective gene 
induction by nickel (Ni).  In airway epithelial (BEAS-2B) cells, Cr(VI) activated signal 
transducer and activator of transcription 1 (STAT1)-dependent signaling within 1 h of exposure.  
This activation was dependent on Src family kinases (SFKs) since inhibiting SFKs prevented 
Cr(VI)-stimulated STAT1 signaling.  Moreover, Cr(VI) activated STAT1 in wild-type mouse 
embryonic fibroblast (MEF) cells, but no response was observed in MEF cells null for the SFKs, 
Src, Yes, and Fyn.  However, reconstituting human Fyn in the deficient MEF cells restored the 
Cr(VI) response.  These data indicate that Cr(VI)-activated STAT1 is mediated by Fyn.  This 
signaling may be detrimental as STAT1 has been implicated as an inflammatory mediator in 
asthma patients that is specifically activated in bronchial epithelial cells (1).  Metallothionein 
(MT) and vascular endothelial growth factor A (VEGFA) are involved in protecting the lung 
from injury by sequestering metals and promoting wound repair, respectively.  Ni-induced 
MT2A, the most abundant human isoform, required zinc (Zn) redistribution which directly 
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activated metal transcription factor-1 (MTF-1).  A prolonged induction was mediated by 
secondary signaling pathways.  Cr(VI) negatively regulated the secondary pathway and had no 
effect on Zn mobilization.  For VEGFA induction, Ni activated a complex signaling cascade 
involving ERK.  Ni-stimulated ERK was upstream of hypoxia-inducible factor-1α (HIF-1α) and 
Src-mediated Sp1 transactivation.  Cr(VI) inhibited Ni-activated ERK, HIF-1α stabilization, Src 
phosphorylation, and VEGFA induction.  The current study demonstrated that Cr(VI)-activated 
STAT1 is responsible for the silencing of inducible genes.  In BEAS-2B cells stably expressing 
STAT1 shRNA, Cr(VI) no longer had an inhibitory effect on Ni-induced MT or VEGFA mRNA 
expression and positively interacted with Ni to induce both genes.  These data indicate that 
Cr(VI)-activated STAT1 may play a role in the pathogenesis of Cr(VI)-induced pulmonary 
diseases by silencing the protective gene transcription in the airway epithelium.  
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1.0  INTRODUCTION 
1.1 CHROMIUM OVERVIEW 
Chromium (Cr) is the 21st most abundant metal and the 24th element on the periodic table (2).  Cr 
is naturally occurring in the environment and is found in rocks, animals, plants, and the soil 
(3,4).  It is a transition metal existing predominantly in three valence states: Cr(VI), Cr(III), 
Cr(0) (reviewed in (5)).  Cr(0) is typically present in its metallic form and is oxidized to Cr(III) 
and Cr(VI) during processes such as welding (6).  Cr(III) is a nutrient that regulates insulin and 
cholesterol homeostasis through altering membrane trafficking (7,8).  Cr(VI) exists as a 
chromate oxyanion under physiological conditions and, unlike Cr(III), can readily enter the cell 
through sulfate and phosphate anion channels due to its structural similarity to these anions (5,9).  
Once Cr(VI) enters the cell, greater than 90% is reduced by ascorbate or glutathione to Cr(III) 
within one hour (9,10).  Cr(VI) is reduced through a series of one electron reductions generating 
Cr(V) and Cr(IV) intermediates.  Cr(VI) can also be reduced to Cr(IV) through a two electron 
reduction when high levels of reducing agents are present (5) (Figure 1).  Cr(III) is the final 
oxidized form of Cr found in all biological systems (6).  Cr(VI) itself is not reactive, but Cr(III) 
and the short-lived intermediates produced through the reduction reaction can directly bind to 
proteins and DNA causing deleterious effects (10-12).  Reactive oxygen species (ROS) are also 
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produced during the reduction of Cr(VI) and can react with macromolecules to cause adverse 
effects (5). 
 
Figure 1.  Reduction reaction of Cr(VI). 
  Reprinted from Mutation Research Volume 533.  O'Brien, T. J., Ceryak, S., and Patierno, S. R.  
Compexities of chromium carcinogenesis: role of cellular response, repair, and recovery mechanisms, 3-36: 
2003 with permission from Elsevier. 
1.1.1 Sources of Chromium 
Cr was initially discovered in Siberia in the 1700s as lead chromate and was used as a pigment 
(2).  Natural sources of Cr include continental dust flux and volcanic dust.  However, most of the 
Cr found in the environment is a result of its industrial use.  Cr(VI) is primarily found as 
chromates or dichromates generated by oxidizing chromite in molten alkali followed by 
extraction into water and acidification (3).  Due to its chemical properties, Cr(VI) is widely used 
in industries (2) with the main applications of use including metallurgical applications, chemical 
manufacturing, and refractory processes (2).  Chromates are used in various industries including 
textiles, tanning, dyeing, welding, chrome manufacturing, and wood preservation (3,4) (Figure 
2).     
Combustion of coal and oil and Cr processing industries accounts for most of the Cr 
emitted into the atmosphere (13).  Cr deposited in lakes and rivers eventually settles into 
sediments (13).  Because of the widespread use of Cr, it is present in over half of the National 
Priority List (NPL) waste sites (Figures 3-4) (3,4,13).   
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Figure 2.  Historical uses of Cr in the United States and the western world.  
1.1.2 Human Exposures 
Several million people worldwide are estimated to be exposed to Cr or Cr-containing compounds 
(6).  Exposure to Cr most commonly occurs through inhalation, ingestion, or dermal contact 
although inhalation of Cr poses the greatest risk.  Environmental exposure to Cr arises from 
urban particulate matter and exhaust, proximity to industrial sites and toxic waste sites (6), from 
cigarette smoke, and as a soil and water contaminant (13).  In the United States, Cr is found in 
soil at an average of 40 ppm (2).  Cr concentrations in fresh water range from 1 to 10 ppb (14).  
The concentration of Cr in the air ranges from 0.001 to 0.01 µg/m3, but urban areas have higher 
levels with an estimated concentration of 0.03 µg/m3 (13).  Exposure to high levels of Cr is more 
likely in the occupational setting, specifically for workers in the stainless steel welding, chromate 
production, chrome plating, ferrochrome industry, chrome pigments industries (13).  Depending 
on the industry, exposures can be higher than 100 mg/m3 (5).  Occupational exposures of Cr(VI) 
are of greater concern than Cr(III) since Cr(VI) readily enters the epithelial cells lining the 
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respiratory tract (11,13).  Exposure to Cr can be monitored in blood, urine, hair, and nails, but it 
is difficult to differentiate between species of Cr (13). 
The guidelines set by the environmental protection agency (EPA) for safe levels of 
Cr(VI) in the drinking water are 100 µg/L per day.  The Occupational Safety and Health 
Administration (OSHA) set a legal limit of 0.005 mg/m3 in the air for a 8 hour workday, 40 hour 
workweek for Cr(VI) (13).   
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Figure 3.  Frequency of NPL sites with Cr contamination. 
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Figure 4.  Frequency of NPL sites with Cr(VI) contamination. 
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1.1.3 Adverse Health Effects 
The primary route of Cr(VI) exposure is through inhalation.  Due to the rapid reduction of 
Cr(VI) to Cr(III), the main target of Cr(VI) exposure is the respiratory tract and airway 
epithelium (11).  Exposure to Cr(VI) results in airway irritation, airway obstruction, and lung 
cancer (13).  Chronic inhalation of chromate dust leads to chronic irritation of the airway, polyps 
of the upper respiratory tract, emphysema, and chronic bronchitis (13).  Pulmonary sensitization 
has also been reported to result in an asthmatic response (13).  However, the severity of the 
disease state varies greatly and depends on the dose, length of exposure, and Cr species (5).   
1.1.4 Cr(VI) Effects on Gene Expression 
Cr(VI) rarely affects constitutive gene expression (15,16) but differentially affects inducible genes in vivo 
and in vitro (16-19).  The traditional view for how Cr(VI) inhibits inducible gene expression is 
through genotoxic mechanisms.  Exposure to Cr(VI) causes DNA damage including formation of 
DNA adducts, single strand breaks, DNA-protein cross-links and DNA interstrand crosslinks 
(5,20).  The type of damage is dependent upon the Cr species generated from Cr(VI) metabolism 
(Figure 5).  Cr(III), the short-lived and unstable Cr(IV) and Cr(V) intermediates, and ROS 
produced through the reduction reaction are all highly reactive with DNA (5).  Cr(V) and Cr(IV) 
can catalyze ROS through Fenton-like reactions with hydrogen peroxide (21).  The role of ROS 
in the deleterious effects of Cr(VI) remains controversial.  The amount of ROS produced depend 
largely on the concentrations of Cr(VI) used.  Low level, non-cytotoxic concentrations of Cr(VI) 
produce detectable amounts of ROS, however, it is not required for Cr(VI) effects on cell 
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signaling (22).  Exposure to Cr(VI) may result in the direct binding to the chromatin which is 
exists in a more open state in inducible genes compared to constitutive gene (16,17).  Moreover, 
exposure to Cr(VI) also suppresses RNA synthesis likely by creating lesions in GC-rich regions 
of DNA that prevents RNA polymerase from elongating the nascent RNA chain (5).   
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Figure 5.  Major pathways involved in the formation of genetic lesions by Cr. 
Schematic illustrates the interrelationships between Cr metabolism and genotoxicity (5). 
  Reprinted from Mutation Research Volume 533.  O'Brien, T. J., Ceryak, S., and Patierno, S. R.  
Compexities of chromium carcinogenesis: role of cellular response, repair, and recovery mechanisms, 3-36: 
2003 with permission from Elsevier. 
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However, there is emerging evidence indicating epigenetic mechanisms by which Cr(VI) 
alters transcriptional activation and complex formation (19,23-25).  Our laboratory has 
demonstrated that Cr(VI) inhibits basal and arsenic-stimulated heme oxygenase 1, a key 
cytoprotective gene, in vivo and in vitro (19) through the sequestering the critical transcription 
factor, nuclear E2 related factor 2 (Nrf2), in the cytosol.  In its inactive state, Nrf2 remains bound 
to kelch-like ECH-associated protein 1 (Keap1) in the cytosol and Cr(VI) may prevent the 
release of Nrf2 from this complex.   Cr(VI) prevents zinc (Zn)- and cadmium (Cd)-induced 
metallothionein (MT) expression by disrupting the essential transcription factor, metal 
transcription factor-1 (MTF-1), from binding to the MT promoter (23).  Although the precise 
mechanism in not known, Cr(VI) interferes with the recruitment RNA polymerase II to the MT 
promoter (25).  TNFα-induction of IL-8 is prevented by preincubation with Cr(VI) which inhibits 
the interaction between NF-κB and co-activators (26).  Cr(VI) silences polycyclic aromatic 
hydrocarbon (PAH)-induced gene expression by preventing the liberation of histone deacetylase 
1 (HDAC1) from the promoters, thereby interfering with the recruitment of co-activators (24).  
Interestingly, this effect was not gene-specific; instead having a global effect on PAH-induced 
genes (24).  Together these studies reveal a possible mechanism that Cr(VI) may activate cell 
signaling to repress gene expression since the repression is not specific to the stimulus or the 
gene endpoint.  Furthermore, the negative regulation of gene induction by Cr(VI) occurs 
independent of cell type as these effects are found in airway epithelial cells and type II cells, as 
well as other non-lung cell types.  Cr(VI) also induces numerous stress responses including cell 
cycle arrest, DNA damage, and apoptosis (5,27-29) that may play a role in repressing gene 
expression.   
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1.2 NICKEL OVERVIEW 
Nickel (Ni) is a naturally occurring metal; the 24th most abundant element.  Ni is widely used in 
industry due to its resistance to corrosion and heat, strength, and conductivity (30).  Although Ni 
can be found in several oxidation states, Ni(II) is the most prevalent species (30).  Ni compounds 
are separated into two groups based on their solubility in water.  Ni carbonates (NiCO3), sulfides 
(Ni3S2), and oxides (NiO) are insoluble; Ni chlorides (NiCl2), sulfates (NiSO4), and nitrates 
(Ni(NO3)2) are soluble.  Soluble Ni readily enters the cell through calcium and magnesium 
channels and the similarity in structure to these essential metals and other divalent cations may 
contribute to Ni toxicity (30,31).  Since Ni sulfate is the major species found in the ambient air 
(32), it is the species used in this thesis research.   
1.2.1 Sources of Ni 
The majority of Ni mining occurs in Canada and Russia.  Most Ni is combined with other metals 
such as Cr, copper (Cu), cobalt (Co), iron (Fe), and Zn to manufacture alloys because of its 
corrosion and heat resistance, hardness, and strength (Table 1) (30).  Ni is also used to produce 
jewelry, coins, and in nickel plating and manufacturing (6).  Nil salts are used in electroplating, 
ceramics, pigments, and as catalysts (30).  Although the Ni from these industries is released into 
the air, Ni is also found in industrial waste waters and in the soil and sediments (30).  Currently, 
Ni is found in over half of the NPL waste sites (Figure 6) (30).  In the United States, a large 
portion of Ni is released into the atmosphere primarily from coal and oil combustion and from 
industries that make or use Ni or Ni-containing compounds.   
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Table 1.  Ni consumption by use in 2002. 
Use Percentage 
Stainless and heat-resistant steel 61% 
Ni-Cu and Cu-Ni alloys 4% 
Other Ni alloys 13% 
Electroplating 6% 
Superalloys 9% 
Other 7% 
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Figure 6.  Frequency of NPL sites with Ni contamination. 
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1.2.2 Human Exposures 
Ni is a main component of air pollution (33,34), cigarette smoke (35), diesel exhaust (36), and 
welding fumes (37,38).  The major route of exposure is through inhalation, but Ni can also be 
ingested from contaminated water and food, and through skin contact (30,32).  The guidelines set 
by the EPA for safe levels of Ni in the drinking water are 0.1 mg/L per day.  OSHA set a legal 
limit of 1.0 mg/m3 for a 8 hour workday, 40 hour workweek for Ni (30).  However, the EPA 
estimates the average Ni concentration is 2.2 ng/m3 in ambient air and 2-4.3 ppb in water (30).  
Exposures are greater to workers in Ni industries that result from breathing Ni-containing fumes 
(30) and levels in Ni refineries have been estimated at 1-5 mg/m3 for soluble Ni (32).  The 
amount of Ni found in ambient air is variable with the highest concentrations found near Ni 
industries and in urban areas (39) and absorption of Ni depends on the route of exposure (Table 
2) (32).  Despite the route of exposure, Ni is excreted in urine (30).   
 
Table 2.  Levels of daily Ni intake by humans from different types/routes of exposure. 
Type/Route of Exposure Daily Ni Intake (µg) Absorption 
Foodstuffs <300 <15% 
Drinking water <20 <15% 
Ambient air (urban dweller) <0.8 50% 
Ambient air (smoker) <23 50% 
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1.2.3 Adverse Health Effects 
Chronic inhalation of soluble Ni causes non-cancer pulmonary diseases; whereas insoluble Ni is 
more carcinogenic due to it prolonged retention in the lung (6).  50% of Ni is retained in lungs 
and the respiratory tract is a major target organ (Table 2) (30,32).  High levels of Ni were found 
in the urine of automobile spot welders and this exposure was associated with pulmonary 
diseases including airway irritation (38).  Ni can cause inappropriate immune responses (40,41), 
asthma (42,43), acute lung injury (ALI) (37,44,45), and cardiopulmonary diseases (33,38).  
However, the pathogenesis of these diseases remains unknown.  Also, chronic dermal contact 
with Ni results in hypoallergic responsiveness with 10-20% of the country’s population being 
sensitive to nickel (30). 
1.3 MIXED EXPOSURES 
Cr(VI) and Ni are found together in over half of the NPL waste sites.  Exposures to these metals 
often occur in industries (e.g. electroplating and stainless steel welding) and are also components 
of coal and oil combustion.  Epidemiological studies associate exposure to metal mixtures with 
exacerbated pulmonary diseases.  A metal plating worker exposed to Cr and Ni experienced 
airway reactivity and developed asthma (46).  In a study from Japan, lung tissues were analyzed 
to determine if metals correlated to emphysema.  It was concluded that the detected levels of Cr, 
Ni, and lead represented environmental exposures that increased with age and the severity of 
emphysema (47).  Workers who were chronically exposed to Cr(VI) and Ni fumes from 
electroplating developed asthma.  Bronchial challenge tests revealed that the fumes from these 
   
 16 
metals are a significant cause of occupational asthma (42).  A case-controlled study in Taiwan 
examined the metal concentrations in lung tumors to determine if the metals, either 
independently or through the production of ROS, contributed to tumorigenesis (48).  A 
significant increase in Cr and Ni levels were observed in lung tumors compared to non-cancer 
controls suggesting that exposure to these metals may contribute to lung cancer (48).  Painters 
using a high-temperature spray paint were diagnosed with interstitial pneumonia caused by 
inhalation of nickel and chrome fumes (49).  Although these studies reveal that exposures to 
metal mixtures are common and may increase the risk of pulmonary diseases, little is known 
about the mechanisms of the individual metals or how they can possibly interact to promote 
diseases. 
1.4 STAT FAMILY OF TRANSCRIPTION FACTORS 
Signal transducers and activators of transcription (STAT) are a family of latent cytoplasmic 
transcription factors.  There are seven members (STATs 1, 2, 3, 4, 5A, 5B, and 6) that all contain 
a N-terminal domain, coiled-coil domain, DNA binding domain, a linker domain, Src homology 
2 (SH2) domain, and a C-terminal transactivation domain (Figure 7) (51).  The conserved N-
terminal domain and coiled-coil domain facilitate protein interactions with non-STAT proteins 
such as co-activators or other transcription factors (50).   
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Figure 7.  Structure of STAT proteins. 
  Reprinted with permission from Macmillian Publishers Ltd: Nat. Rev. Mol Cell Biol 3, 651-662, 2002. 
 
Extracellular stimuli or cytokines interact with cell surface receptors or non-receptor 
tyrosine kinases that activate the STATs through phosphorylation on a conserved tyrosine 
residue located in the C-terminus.  The SH2 domain regulates the tyrosine phosphorylation of the 
STATs and also promotes STAT dimerization and translocation into the nucleus to initiate gene 
expression (52).  The Janus kinase (JAK) protein tyrosine kinase family was initially identified 
as the critical kinases in the activation of the STATs (53).  However, STATs can be directly 
activated by receptors with intrinsic kinase activity or indirectly through the recruitment of non-
receptor tyrosine kinases (NRTKs).  The NRTKs include the Src family kinases (SFKs) which 
can initiate the STAT signaling pathway (Figure 8) (51,54-56).  Although there is great 
homology between the family members, the STAT proteins are selectively activated by various 
stimuli resulting in diverse biological effects (52). 
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Figure 8.  Mechanisms of STAT signaling. 
  Reprinted with permission from Macmillian Publishers Ltd: Nat. Rev. Mol Cell Biol 3, 651-662, 2002. 
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1.4.1 STAT1 
STAT1 was the first of the STAT proteins discovered.  It was originally identified as a 
downstream effector of type I interferon (IFN) (e.g. IFN-α) and type II IFN (e.g. IFN-γ) 
stimulation (57).  Through deletional and mutational analysis, the DNA sequences responsible 
for IFN-α and IFN-γ transcription were identified as interferon-stimulated response element 
(ISRE) and IFN-γ activation site (GAS), respectively (reviewed in (57)).  Type I IFNs bind to the 
interferon α/β receptor (IFNAR), stimulating STAT1 and STAT2 tyrosine phosphorylation and 
subsequent dimerization.  A heterotrimeric complex, interferon-stimulated gene factor 3 
(ISGF3), is formed after interferon regulatory factor 9 (IRF9) binds the STAT1/STAT2 
heterodimer.  Following the translocation of this complex to the nucleus, it binds to ISRE 
elements to drive transcription of certain genes (e.g. IRF7).  The interaction of STAT1 and 
STAT2 with IRF9 is required for optimal binding to the ISRE (52,58).  Type I IFNs can also 
activate STAT1 homodimers which bind to GAS elements to transactivate GAS-driven genes 
(e.g. IRF1).  In contrast, type II IFNs can only induce STAT1 homodimers (reviewed in (59)).  
Type I IFN-stimulated gene transcription also requires HDAC1 to interact with both STAT1 and 
STAT2 (60).  HDAC activity does not affect the activation of STAT1 or 2, the dimerization, or 
the nuclear translocation of the ISGF3 complex.  Instead, HDAC recruits RNA polymerase II to 
the promoter to initiate transcription of ISRE-driven genes (60,61). 
Recently, the ISGF3 complex has emerged as having an important role in mediating 
cellular responses.  All three protein components of this complex are required for the inhibition 
of MMP9 (62) and IL-8 (63) induced by IFN-β.  Surprisingly, this inhibition does not occur 
through direct binding to the promoter of these genes, nor does it affect the activation of 
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upstream proteins in the signaling pathway (62,63).  Instead, this complex interferes with the 
recruitment of transcription factors and co-activators to the promoter through an unknown 
mechanism (62).  The activation of ISGF3 may induce other proteins that directly interfere with 
these inducible genes or that there is competition with co-activators (e.g. CBP/p300) that may 
prevent the gene induction (62). 
1.4.2 Pathophysiological Role of STAT1  
STAT pathways can be activated in response to exogenous stresses (64-66) including metals 
(55).  STAT1 is required to induce antiviral and antiproliferative responses (67,68).  It promotes 
apoptosis in cardiac myocytes after ischemia and reperfusion by inducing pro-apoptotic genes 
(64).  It can also interact with and increase the transcriptional activity of p53 (64,69).  Moreover, 
STAT1 has been implicated in the pathogenesis of lung diseases (70) where it is selectively 
activated in the airway epithelial cells of asthmatic patients leading to the transcription the 
STAT1-dependent genes (1).  STAT1 activation is independent of IFN and this inflammatory 
process was specific to STAT1 and not other inflammatory transcription factors (e.g. NF-κB).  
These data suggest that inappropriate STAT1 signaling contributes to the development of 
pulmonary inflammatory diseases (1).  Moreover, aberrant expression of STAT1 in the airway 
may be a precursor to disease. 
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1.5 SRC FAMILY KINASES 
Src family kinases (SFK) are cytoplasmic NRTKs involved in diverse biological functions 
including cell proliferation, migration, differentiation, and survival (71).  There are 11 known 
members of which 8 are well-characterized (72).  Src, Yes, and Fyn are ubiquitously expressed, 
while the other family members are more cell-type specific (71).  These kinases contain 6 
functional domains, as depicted in Figure 9 (71).  The SH4 domain is responsible for lipid 
modification that is aided by a myristoylation at the glycine at position 2.  Palmitoylation can 
occur in this domain, as well (73).  These modifications are required to recruit the SFK to the 
cellular membrane.  The SH4 domain is followed by a unique domain.  This domain, although its 
function remains unclear, is proposed to be responsible for interactions or signaling that is 
specific to each family member.  The SH3 domain is composed of 50 amino acids that bind to 
proline-rich residues and is essential for negative regulation of catalytic activity, localization, and 
substrate recruitment (71).  The SH2 domain also regulates the catalytic activity and localization 
of SFK through phosphotyrosine-containing sequences.   
 
Figure 9.  Structure of SFKs. 
Reprinted, with permission, from the Annual Review of Cell and Developmental Biology, Volume 
13 © 1997 by Annual Reviews  www.annualreviews.org .  
The SH2 and SH3 domains regulate the kinase activity of SFKs.  As shown in Figure 10 
(71), there is an inhibitory tyrosine residue 527 in the C-terminal tail that is phosphorylated by  
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C-terminal Src kinase (Csk).  The SH2 domain interacts with this residue to inhibit SFK kinase 
activity (71).  The SH3 domain binds with sequences in the catalytic domain and linker region 
thereby connecting the SH2 and catalytic domains (73).  These interactions keep the kinase in a 
closed and inactive conformation.  SFKs are activated by the dephosphorylation of tyrosine 527 
by a protein tyrosine phosphatase, followed by the autophosphorylation of tyrosine 416 located 
in the C-lobe of the catalytic domain and the disruption of the interactions between the SH2 and 
SH3 domains.  Once activated, SFKs facilitate downstream signaling by transferring the 
phosphate to substrate proteins (71). 
 
Figure 10.  Conformations of SFKs. 
Reprinted, with permission, from the Annual Review of Cell and Developmental Biology, Volume 13 © 
1997 by Annual Reviews  www.annualreviews.org . 
SFKs can be activated through interactions with receptors (e.g. G protein-coupled 
receptors (GPCRs) or receptor protein tyrosine kinases (RPTK)), ligand activation of these 
receptors, or by stress responses (71).  Metals, including Ni, Cd, arsenic, and cobalt have been 
shown in vitro to directly bind to the C-lobe of the catalytic domain of protein tyrosine kinases 
(PTKs) (74).  Only PTKs containing cysteines in the C-lobe (e.g. Src, Fyn) are conformationally 
changed in response to incubation with metals (74).  Cr(VI) directly activated  Fyn in vitro and 
incubation of A549 cells with Cr(VI) activated Fyn and Lck, but had no, or even an inhibitory, 
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effect on Src and Yes (22).  This activation did not require ROS production.  However, 
increasing the thiol pool in the cells through the addition of N-acetyl-L-cysteine (NAC) 
prevented Cr(VI) activation of SFKs suggesting that Cr(VI) directly binds to the thiol containing 
regulatory domain of SFKs (22). 
1.6 PROTECTIVE MECHANISMS IN THE LUNG 
1.6.1 METALLOTHIONEIN 
Metallothioneins (MT) are low molecular weight, highly conserved, intracellular proteins.  There 
are 4 isoforms of mouse MT: MT1-4; and 10 functional isoforms of human MT including 
multiple isoforms of MT1 (reviewed in (75,76)).  MT1 and MT2 are the most commonly 
expressed in mammals with MT2A being the most abundantly expressed gene isoform in human 
tissues (75).  MT3 is expressed mostly in the brain (77) and MT4 is only detected in certain 
tissues, specifically the squamous epithelium (78). 
The main function of MT is maintaining metal homeostasis.  Due to the unique thiol-rich 
structure of MT, it is able to sequester heavy metals and plays an important role in protecting the 
cells from heavy metal toxicities and in maintaining Zn homeostasis (76,79,80).  MT is induced 
by and can bind 18 different metals, including Ni (81,82).  The cysteine residues of MT can 
interact with up to 7 divalent or 14 monovalent metals per molecule with varying affinities (76).  
MT can also be induced by inflammatory mediators (83) and environmental insults such as ROS, 
nitric oxide, and ultraviolet light (UV) (76,84).   
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1.6.1.1 MT Expression in the lung 
Tissue expression of MT is the highest in the liver, pancreas, kidney, and intestine (76), but is 
also expressed in the lung.  MT levels are dramatically increased in the lungs of mice exposed to 
Ni (82), diesel exhaust particles and lipopolysaccharide (LPS) (85), during hyperoxia (86), and 
during inflammation (87).  Furthermore, the role of MT in protecting the lung from various 
stressors was elucidated by utilizing Mt-transgenic mice that express two times the basal MT 
protein expression in the lung and Mt1/2(-/-) mice that are null for Mt1 and Mt2.  Compared to 
wild-type mice, Mt1/2(-/-) mice exposed to Ni had increased inflammation, permeability, and 
death (44).  Other studies demonstrated that Mt1/2(-/-) mice had increased inflammatory cell 
recruitment, cytokine expression, and oxidative damage induced by an antigen-related 
inflammation model (87).  Furthermore, the MT-transgenic mice are resistant to Ni- (44) and Cd- 
(75) induced injury.  MT was also protective against LPS-induced injury by enhancing 
pulmonary integrity and scavenging free radicals (83).  Overall, these studies support the notion 
that MT plays a crucial role in protecting the lung against damage and promoting survival. 
1.6.1.2 Mechanisms of MT induction 
MT is primarily transcriptionally regulated (75).  The MT promoter contains numerous cis 
elements, but the main transcription factor involved in its induction is MTF-1.  MTF-1 contains 
six zinc fingers of the C2H2-type, is highly conserved, and ubiquitously expressed in the cytosol.  
MTF-1 is required for embryogenesis, since mice lacking MTF-1 die in utero from liver 
degeneration (88).  The embryonic lethality is not a result of the lack of MT transcription, as 
Mt1/2(-/-) mice are viable.  MTF-1 regulates other genes included enzymes needed for glutathione 
biosynthesis that may be essential for liver function and cell proliferation (88).  The embryonic 
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fibroblasts isolated from these mice are more sensitive to metal and free radical-induced insults 
(88).   
MTF-1 acts like an intracellular Zn sensor and rapidly translocates to the nucleus upon 
activation to bind metal response elements (MRE) and initiate gene transcription (89,90).  MTF-
1 is required for both basal and metal-induced MT (90).  Although there are many agents known 
to induce MT, the mechanism of its induction is only known for Zn.  Zn directly and reversibly 
binds to MTF-1 leading to its activation (90).  Large concentrations of Cd are able to activate 
MTF-1, but this is not from Cd activating MTF-1 directly.  Instead, this may be through the 
redistribution of Zn (89).  It is likely that other transition metals stimulate MT through indirect 
mechanisms (91).  The activation of upstream kinases, such as c-Jun-N-terminal kinase (JNK) 
and protein kinase C (PKC), can phosphorylate and activate MTF-1 (90-92).  MTF-1 also 
cooperates with other transcription factors, such as hypoxia-inducible factor-1  α (HIF-1α) 
(93,94) and Sp1 (95,96), that may affect MT expression. 
1.6.2 Vascular endothelial growth factor A  
The vascular endothelial growth factor (VEGF) family contains five members in mammals: 
VEGFA, B, C, D, and placenta growth factor (PLGF).  These proteins are secreted, mitogenic, 
glycoproteins.  The expression of each family member is tissue-specific and dependent on the 
stimulating factor (reviewed in (97)).  VEGFA is the predominant and most studied family 
member. VEGFA was initially named vascular permeability factor (VPF) as it was discovered 
for its role in the induction vascular permeability (97).  VEGFA is alternatively spliced 
producing six isoforms, 121, 145, 165, 183, 189, and 206, which only differ by the presence or 
absence of exons 6 and 7 (98).  VEGFA121, VEGFA165, and VEGFA183 are preferentially 
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expressed whereas VEGFA145 and VEGFA206 are rare isoforms (98).  VEGFA165 is the most 
abundant and will be referred to simply as VEGF or VEGFA throughout this dissertation.   
1.6.2.1 VEGFA expression in the lung 
VEGFA is most abundantly expressed in the lung, kidney, and spleen.  VEGFA is important for 
lung development (99) and deletion of a single allele in a mouse model is embryonic lethal (97).  
There is an intricate balance of expression of VEGFA required for normal lung development; 
overexpression of VEGFA in a transgenic mouse model disrupts lung morphogenesis and causes 
inappropriate vessel development (100).  However, less is known of its role in the airway 
epithelium and lung injury repair.  The bronchial epithelial cells and alveolar epithelial cells are 
the major source of VEGFA in the lung (99,101) and it is necessary for airway cell proliferation 
(102).  In specific lung-targeted VEGFA knockout mice, an emphysema-like phenotype is 
observed (103).  VEGFA is elevated in patients with inflammatory pulmonary diseases, such as 
asthma, chronic bronchitis (104,105), ALI, and acute respiratory distress syndrome (ARDS) 
(105,106).  It is decreased in patients developing bronchopulmonary dysplasia (107), in 
emphysema (105), and during ischemia and reperfusion (108).  Furthermore, VEGFA 
overexpression protects against pulmonary hypertension in rats (109) and during hyperoxia in 
mice overexpressing IL-13 (106).   
It is hypothesized that the varying levels of VEGFA during lung injury (ALI or ARDS) 
are due, in part, to the different stages of the disease process (106).  When the injury initially 
occurs, the epithelial cells and certain inflammatory cells (e.g. neutrophils and macrophages) 
secrete VEGFA.  The high levels of VEGFA cross the endothelial barrier and increase 
permeability of endothelium to promote edema, leading to epithelial cell damage and death.  The 
loss of epithelial cells leads to a decrease in VEGFA secretion.  However, as the epithelial cells 
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recover, VEGFA can be secreted to promote angiogenesis and lung repair (106,110,111).  This 
hypothesis is substantiated by the observation that decreased VEGFA protein observed during 
ischemia and reperfusion is associated with epithelial cell damage (108).  Furthermore, VEGFA 
secreted by bronchial epithelial cells promotes endothelial repair in the lung (112) and promotes 
wound repair while preventing apoptosis (113).  Also, increasing VEGFA levels is associated 
with the resolution of ARDS (114) and is upregulated during the wound healing in vivo (115). 
1.6.2.2 Mechanisms of VEGFA induction 
HIF-1α is the major stimulus for VEGFA induction.  HIF-1α is a heterodimeric basic-helix-loop-
helix-PAS transcription factor (116).  The main inducer of HIF-1α is molecular oxygen (117). In 
the presence of oxygen, prolyl hydroxylases post-transcriptionally modify HIF-1α leading to its 
interaction with the von-Hippel Lindau (VHL) complex.  The VHL complex mediates the 
ubiquination of HIF-1α.  In the absence of oxygen, prolyl hydroxylases cannot modify HIF-1α 
and it is stabilized.  Once stabilized, HIF-1α can translocate into the nucleus and bind to 
hypoxia-responsive elements (HRE) and activate transcription of its target genes (116).  Metals, 
including Ni, stabilize and transactivate HIF-1α in the presence of oxygen (118-121); although 
the exact mechanism remains unknown.  It may result from a direct inhibitory effect on the 
prolyl hydroxylases marking the protein for degradation (122).  The prolyl hydroxylases contain 
an iron moiety that Ni has been predicted to displace (122) resulting in the inactivation of the 
enzyme.   
VEGFA expression and HIF-1α stabilization have been shown to be upregulated through 
the activation of kinases including SFKs, phosphoinositide 3-kinases (PI3K), and mitogen-
activated protein kinases (MAPKs) (118,120,121,123).  Also, HIF-1α cooperates with other 
transcription factors (e.g. Sp1, activator protein 1 (AP-1), STAT3) to induce VEGFA (124-126); 
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although there is evidence of HIF-1α-independent mechanisms of VEGFA induction (127,128).  
Furthermore, phosphorylation of Sp1 is required for full induction of VEGFA (129,130).  Sp1 is 
one of 4 members of zinc finger transcription factors, is widely expressed, and binds to GC 
motifs in promoters producing broad and diverse biological responses (131).  Sp1 has three 
major functions: DNA binding, promoter activation, and protein-protein interactions.  There are 
5 different phosphorylation sites (Ser59, Ser131, Thr453, Thr579, and Thr739) that contribute to 
the function and activity of Sp1.  The two serine sites and Thr453 are located in the 
transactivation domains in the N terminus and are involved in promoter activation.  
Phosphorylation of Thr579 has been correlated with DNA binding and Thr739 is important for 
facilitating protein interactions (131).  Sp1 is phosphorylated by various kinases including ERK, 
cyclin-dependent kinases, and DNA-PK.  ERK has been implicated in the phosphorylation of 
Thr453 and Thr739 resulting in decreased activation of the VEGFA promoter (131).  The 
phosphorylation of Sp1 conveys both positive and negative effects on the regulation of the target 
genes.  The dephosphorylation of Sp1 through the activation of the serine/threonine 
phosphatases, protein phosphatases 1 and 2A (PP1 and PP2), also has a crucial role in Sp1-
dependent gene induction.  Thus, activation of both kinases and phosphatases can regulate Sp1-
dependent VEGFA induction. 
1.7 STATEMENT OF THE PROBLEM AND HYPOTHESIS 
Cr(VI) and Ni are well-established environmental and occupational hazards that are often found 
together in industry and in over half of the NPL toxic waste sites.  Chronic exposure to each 
metal alone promotes pulmonary diseases.  However, it is likely that humans are exposed to 
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metal mixtures.  Epidemiological studies have associated exposure to metal mixtures to 
increased risk and exacerbated pulmonary diseases and  in vivo studies in rats have shown that 
exposure to welding fumes particles containing a complex of Cr and Ni represses lung defense 
mechanisms (132-134).  However, there are few studies that have addressed how metals may 
interact to worsen these diseases.  
Cr(VI) silences inducible gene expression in vivo and in vitro (19,24) without affecting 
constitutive gene expression (15,24).  While the canonical belief is that Cr(VI) affects the 
inducibility of gene expression by directly binding to the chromatin in the promoter region, 
recent evidence suggest that Cr(VI) exerts epigenetic effects to silence gene induction by altering 
transcriptional complexes (19,23,24).  Cr(VI) activates select SFKs directly, leading to the 
phosphorylation of downstream effectors including members of the STAT family (22,55).  
STAT1 is the primary regulator of antiproliferative and apoptotic effects in response to IFNs 
(135,136) and also opposes other transcription factors capable of promoting protective and repair 
responses, such as HIF-1α, Sp1, and STAT3 (62,137,138).   
The objective of this research was to investigate the potential mechanisms for Cr(VI)-
induced pulmonary disease by defining how Cr(VI) alters transcriptional activity to repress gene 
expression.  The central hypothesis is that Cr(VI) activates STAT1-dependent signaling to 
silence protective gene induction by Ni in human airway epithelial cells.  Thus, the specific aims 
of this dissertation were to 1) probe the upstream kinases mediating Cr(VI)-activated STAT1, 2) 
identify the mechanism for Ni induction of the protective genes, MT and VEGFA, 3) determine 
the effect of Cr(VI)-stimulated STAT1 on Ni-induced MT and VEGFA.  Identifying these 
molecular mechanisms will advance the understanding of the pathogenesis of Cr(VI)-related 
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diseases and elucidate how signaling pathways induced by metals may interact to worsen 
pulmonary diseases.    
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2.0  MATERIALS AND METHODS 
2.1 CELL CULTURE 
2.1.1 BEAS-2B Cells 
Human bronchial epithelial cells (BEAS-2B) (ATCC, Manassas, VA) and the stable BEAS-2B 
cell lines expressing random negative control (shNC) or STAT1 (shSTAT1) shRNA were 
cultured on a matrix of 0.01 mg/ml of human fibronectin (Invitrogen, Carlsbad, CA), 0.029 
mg/ml Vitrogen 100 (COHESION Inc, Palo Alto, CA), and 0.01 mg/ml bovine serum albumin 
(Invitrogen) in LHC-9 medium (Invitrogen).  The parental BEAS-2B cells were cultured in 
LHC-9 media and the stably transfected cell lines were cultured in the same medium 
supplemented with 75 μg/ml G418 (Sigma-Aldrich, St. Louis, MO). The cells were maintained 
at 37ºC under an atmosphere of 5% CO2.  Experiments were performed on 1-day postconfluent 
cells unless otherwise indicated. Medium was changed 12-16 h prior to all experiments. 
2.1.2 Generation of the shNC and shSTAT1 Stable Cell Lines 
Human STAT1 shRNA sequences were designed using the Insert Design Tool for pSilencer™ 
Vectors at www.ambion.com and were subcloned into the pSilencer™ 4.1-CMV neo vector 
(Applied Biosystems, Foster City, CA) using BamHI and HindIII sites according to the 
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manufacturer’s instructions.  The resultant clones were sequenced at the Genomics and 
Proteomics Core Laboratories at the University of Pittsburgh to verify the presence of the 
shRNA.  A negative control expressing random shRNA in the pSilencer™ 4.1-CMV neo vector 
was purchased from Applied Biosystems.  BEAS-2B cells were transfected with either the 
random shRNA or the STAT1 shRNA using Lipofectamine and PLUS reagents (Invitrogen) 
according to the manufacturer’s instructions.  Transfected cells were selected with G418 (75 
µg/ml) (Sigma-Aldrich) and three cell lines were generated for each shRNA.  STAT1 
knockdown was confirmed by western analysis.   
2.1.3 Mouse Embryonic Fibroblasts 
Mouse embryonic fibroblasts (MEF) were grown at 37°C under an atmosphere of 5% CO2 in 
Dulbecco’s Modified Eagle Medium (DMEM) (Invitrogen) supplemented with 10% fetal bovine 
serum (FBS) (Thermo Fisher Scientific, Pittsburgh, PA), 4 mM L-glutamine (Invitrogen), and 
1% penicillin/streptomycin (Invitrogen). The media was changed 12-16 h prior to the experiment 
to media containing 0.1% BSA in replacement of FBS to arrest cell growth.  All MEF cell lines 
are SV-40 immortalized.  Dko7 cells are derived from MTF-1 double knockout embryonic stem 
cells, SYF cells are derived from mouse embryos with functionally null mutations in Src, Yes, 
and Fyn, and Src++ cells are deficient in Yes and Fyn, but express endogenous Src.  Wild-type 
MEF cells are used as the control cells in these experiments.  Wild-type, SYF, and Src++ MEF 
cells were purchased from ATCC.  Dko7 were kindly provided by Dr. Elias Aizenman from the 
University of Pittsburgh. 
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2.1.4 Cell Maintenance and Storage 
All cells were passaged by rinsing once with Ca2+/Mg2+-free Hank’s Buffered Salt Solution 
(HBSS) (Invitrogen).  The cells were incubated for 5 min at room temperature with the second 
rinse of HBSS.  Cells were incubated for 2-3 min with trypsin/EDTA solution (Lonza Group 
Ltd., Basel, Switzerland) and an equal volume of trypsin neutralizing solution (TNS) (Lonza 
Group Ltd.) was added.  BEAS-2B cells were dislodged by gentle scraping with a rubber 
policeman and MEF cells were dislodged by gently tapping the flask.  Cells were pelleted by 
centrifugation at 1000 rpm for 10 min.  BEAS-2B cells were passaged at a 1:4 ratio and MEF 
cells were passaged at a 1:10 ratio. 
For long-term storage, BEAS-2B cells were frozen in LHC-9 media containing 10% FBS, 
7.5% dimethylsulfoxide (DMSO) (Sigma-Aldrich), and 1% polyvinyl pyrrolidine (PVP) (Sigma-
Aldrich).  MEF cells were frozen in the serum-containing DMEM with 10% DMSO.   
2.2 TREATMENTS 
2.2.1 Metals 
Cr(VI), NiSO4 (Ni), and ZnCl2 (Zn) solutions were prepared fresh from potassium dichromate, 
nickel(II) sulfate hexahydrate, and zinc chloride (Sigma-Aldrich), respectively.  Unless 
otherwise noted, cells were exposed to 5 µM Cr(VI), 200 µM Ni, or 100 µM Zn.  These exposure 
levels are relevant to occupational exposures and are based on our previous demonstration of 
effective increases in cell signaling for gene expression changes without cytotoxicity.    
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2.2.2 Other reagents and chemicals 
IFN-α2 (100 U/ml) (PBL Biomedical Laboratories, New Brunswick, NJ) and IFN-γ (100 ng/ml) 
(R&D Systems, Minneapolis, MN) were used as positive controls for ISRE and GAS activation, 
respectively.  The ionophore, 2-mercaptopyridine-N-oxide sodium salt (pyrithione) (5 µM) 
(Sigma-Aldrich), was added to facilitate the entry of Ni and Zn into the cell.  U0126 (10 µM), 
SB203580 (20 µM), PP2 (10 µM), and wortmannin (1 µM) (EMD Biosciences, San Diego, CA) 
were used to inhibit ERK, p38, SFK, and PI3K, respectively.  Sodium butyrate (NaB) (2 mM) 
(Sigma-Aldrich) was used to inhibit HDAC activity.  N-acetyl-L-cysteine (NAC) (2 mM) 
(Sigma-Aldrich) was added to increase intracellular pools of thiols.  L-ascorbic acid (AA) (2 
mM) (Sigma-Aldrich) was used as an antioxidant.  N,N,N’,N’-Tetrakis(2-
pyridylmethyl)ethylenediamine (TPEN) (5 µM) (Sigma-Aldrich) was added to chelate Zn.  
Mouse monoclonal antibody against human IFNα/β receptor chain 2 (IFNAR) (1 µg/ml) (PBL 
Laboratories) was used to neutralize the human IFN-α receptor. 
2.3 DETERMINATION OF PROTEIN LEVELS AND LOCALIZATION 
2.3.1 Total Protein Isolation 
For analysis of HIF-1α and total STAT1, cells were rinsed twice with stop buffer and lysed in 
boiling lysis buffer (Table 3).  Lysates were boiled for an additional 5 minutes.  For analysis of 
MT, after the lysate was boiled for 5 min, it was incubated with tris(2-carboxyethyl)phosine 
(Sigma-Aldrich) (1 mM) for 15 min at 37°C followed by a 30 min incubation with 20 mM 
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iodoacetamide (Sigma-Aldrich) at 37°C.  For analysis of ERK, cells were rinsed twice in stop 
buffer and lysed in modified RIPA buffer (Table 3) supplemented with sodium orthovanadate 
and protease inhibitors.  Lysates were incubated on ice for 30 min and centrifuged at 13,000g for 
15 min at 4°C.   
2.3.2 Nuclear and Cytosolic Protein Isolation 
Nuclear protein was isolated by rinsing twice in stop buffer and scraping in stop buffer (Table 3).  
Lysates were centrifuged at 400g for 10 min at 4°C.  The pellet was resuspended in 100 µl of 
buffer A, incubated on ice for 10 min, and centrifuged at 13,000g for 2 min at 4°C.  The 
supernatant (cytosolic fraction) was transferred to a new tube.  The pellet was rinsed with 100 µl 
buffer A and centrifuged at 13,000g for 2 min at 4°C.  The pellet was resuspended in 15 µl of 
buffer C, vigorously shook for 15 min at 4°C, and centrifuged at 13,000g for 5 min at 4°C.  The 
supernatant (nuclear fraction) (15 µl) was transferred to a new tube and 22.5 µl of buffer D was 
added.  Protein concentrations were determined by measuring the absorbance (595 nm) after the 
addition of Coomassie blue dye (Thermo-Fisher Scientific) using BSA as a reference standard.   
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Table 3.  Buffers 
Buffer Formulation Purpose 
Stop buffer 10 mM Tris-HCl, pH 7.4, 10 mM EDTA, 5 mM 
EGTA, 0.1 M NaF, 0.2 M sucrose, 100 µM sodium 
orthovanadate 
Protein isolation 
Buffer A 10 mM HEPES, pH 7.9, 0.1 mM EDTA, 0.1 mM 
EGTA, 10 mM KCl, 1 mM DTT, 0.1% NP-40, 100 
µM sodium orthovanadate 
Nuclear protein 
isolation 
Buffer C 20 mM HEPES, pH 7.9, 0.4 M NaCl, 1 mM EDTA, 
0.1 mM EGTA, 1 mM DTT, 100 µM sodium 
orthovanadate 
Nuclear protein 
isolation 
Buffer D 20 mM HEPES, pH 7.9, 20% glycerol, 0.1 M KCl, 1 
mM EDTA, 0.1 mM EGTA, 0.1% NP-40, 1 mM 
DTT, 100 µl sodium orthovanadate 
Nuclear protein 
isolation 
SDS Lysis 
buffer 
20 mM Tris, pH 7.5, 1% SDS Protein isolation 
Modified RIPA 
buffer 
50 mM Tris, pH 7.6, 150 mM NaCl, 1 mM EDTA, 10 
mM NaF, 1% Triton X-100, 0.1% SDS 
Protein isolation 
Luciferase 
assay lysis 
buffer 
25 mM glycylglycine, 4 mM EGTA, 15 mM MgSO4, 
1% Triton X-100, 1 mM DTT 
Luciferase assay 
 
Luciferase 
assay buffer 
25 mM glycylglycine, 15 mM KH2PO4, 15 mM 
MgSO4, 4 mM EGTA, 2 mM ATP, 1 mM DTT 
Luciferase assay 
TTBS 10 mM Tris-HCl. pH 8.0, 150 mM NaCl, 0.05% 
Tween-20 
Washing membranes 
and diluting 
antibodies 
Towbin’s 
Transfer Buffer 
25 mM Tris, 192 mM glycine, 20% methanol, 0.01% 
SDS 
Westerns 
SDS sample 
buffer 
62.5 mM Tris-HCl, pH 6.8, 10% glycerol, 2% SDS, 
5% β-mercaptoethanol, 0.05% bromophenol blue 
Westerns 
PBS 0.136 M NaCl, 3 mM K Cl, 8 mM Na2HPO4, 2 mM 
KH2PO4 
Rinsing cells 
LB Broth 170 mM NaCl, 1% (w/v) Peptone 140, 0.5% (w/v) 
yeast extract 
Plasmid Preparations 
 
 
   
 37 
2.3.3 Western Blotting 
To determine specific protein abundance, cell lysates were resolved by SDS-PAGE and 
transferred to PVDF membranes (Millipore, Billerica, MA).  Membranes were blocked in either 
5% non-fat milk or 5% BSA for 1 h at room temperature and incubated overnight at 4°C with the 
primary antibodies (Table 4) diluted in TTBS (Table 3).  To determine MT protein abundance, 
after the transfer to the PVDF membrane, the membrane was fixed in 2% glutaraldehyde (Sigma-
Aldrich) before incubating with the primary antibody overnight.  After washing the membranes 
three times for 10 min with TTBS, horseradish peroxidase-conjugated secondary antibodies (GE 
Healthcare, Piscataway, NJ) were added for one hour before 3 additional TTBS washes.  The 
proteins were visualized using enhanced chemiluminescence (Perkin-Elmer, Boston, MA) and 
quantification was performed using Image J.   
 
Table 4.  Antibodies 
Antibody Supplier Dilution Purpose 
β-actin Sigma-Aldrich 
(A5441) 
1:10,000 Western  
ERK Cell Signaling 
Technology (CST) 
(Danvers, MA) (9101) 
1:2000 Western  
Fyn Santa Cruz (sc-434) 1:200; 1:1000 IP; western (human) 
Fyn Millipore (06-133) 1:1000 Western (mouse)  
HIF-1α BD Biosciences 
(610958) 
1:500 Western  
MT Dako Cytomation 
(M0639) 
1:500 Western   
pERK CST (9101) 1:2000 Western  
pSFK (Tyr416) CST (2101) 1:1000 Western  
pYSTAT1 Millipore (07-307) 1:1000 Western  
Src CST (2110) 1:200; 1:1000 IP; western 
STAT1 CST (9176) 1:1000 Western (human) 
STAT1 Santa Cruz (sc-346) 1:2000 Western (mouse) 
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2.3.4 Immunoprecipitation 
Cells were rinsed twice in stop buffer and scraped in modified RIPA buffer supplemented with 
sodium orthovanadate and protease inhibitors.  Lysates were incubated for 30 min on ice and 
then sonicated 3 times at 5 sec intervals.  Lysates were centrifuged at 13,000g for 15 min at 4°C 
and the supernatants were collected.  Equal amounts of protein were incubated with the antibody 
against either total Src or total Fyn overnight at 4°C on a rotating platform.  Protein A/G beads 
(Thermo-Fisher Scientific) were added and incubated for an additional 3 h at 4°C.  The beads 
were collected by centrifugation at 13,000g for 1 min, rinsed 3 times with modified RIPA buffer 
supplemented with sodium orthovanadate and protease inhibitors, suspended in 2X sample 
buffer, and boiled for 5 min.  
2.3.5 MTF-1 Localization 
Cells were transiently transfected with eGFP-MTF-1 and after twenty-four hours, cells were 
trypsinized, replated on chamber well slides, and allowed to attach overnight.  Cells were 
exposed to Ni (200 µM; 30 min to 4 h) and Zn (100 µM; 2 h).  Cells were fixed with 4% 
paraformaldehyde (Sigma-Aldrich) and nuclei were stained with DRAQ5™ (Biostatus Limited, 
Leicestershire, UK).  Images were taken at 60X magnification with an Olympus Fluoview 500 
confocal microscope in the University of Pittsburgh Center for Biological Imaging.  Images were 
quantified by dividing the total number of eGFP-MTF1 positive nuclei by the total number of 
nuclei in each image.   
   
 39 
2.3.6 Enzyme Linked Immunosorbant Assay 
Conditioned medium was collected and stored at -80°C until use.  VEGFA(165 and 121) content in 
the medium was analyzed using Quantikine® VEGFA Immunoassay (R&D Biosystems) 
according to the manufacturer’s instructions.  VEGFA protein release was normalized to total 
cellular protein from each individual sample.  
2.4 RNA ISOLATION AND QUANTIFICATION 
Total RNA was isolated using TRIzol® reagent (Invitrogen) according to manufacturer’s 
instructions.  Briefly, cells were lysed in TRIzol® reagent and incubated for 5 min at room 
temperature.  After transferring the sample to a tube, chloroform was added and samples were 
mixed vigorously for 15 s.  Samples were incubated at room temperature for 2-3 min before 
centrifuging at 11,000g for 15 min at 4°C.  The aqueous layer was transferred to a new tube, 
isopropanol was added, and samples were incubated for 10 min at room temperature before 
centrifuging at 11,000g for 15 min at 4°C.  The supernatant was discarded and the pellet was 
washed with 75% ethanol and centrifuged at 7,500g for 5 min at 4°C.  The pellet was dried and 
resuspended in RNAse- and DNAse-free water.  The RNA was quantified by measuring 
absorbance (260 nm) and was reverse transcribed to cDNA.   
VEGFA, MT2A, Mt1, IRF1, ribosomal protein L13A (RPL13A), and β-actin cDNA 
levels were amplified by real-time PCR using the MJ Research Opticon 2 (Bio-Rad Laboratories, 
Hercules, CA)) with specific primers (Table 5).  Each PCR reaction contained 1X SYBR 
GreenER™ qPCR Supermix (Invitrogen) and 0.4125 pmol each of forward and reverse primers.  
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Thermal cycling was performed by incubating at 50°C for 2 min and 95°C 10 min followed by 
40 cycles of 95°C for 15 s and 57°C for 1 min.  Gene expression was quantified using standard 
curves for both the mRNAs of interest as well the housekeeping genes, RPL13A or β-actin for 
human or mouse cDNA, respectively. 
IRF7 and Irf7 cDNA levels were amplified by conventional PCR using the MJ Research 
PTC-100 Thermocycler (Bio-Rad Laboratories) with specific primers (Table 5).  Thermocycling 
was performed using the following conditions: 95°C for 5 min; 25 cycles or 20 cycles of 94°C 20 
s, 55°C for 30 s, and 72°C for 30 s for IRF7 or Irf7, respectively; and 72°C for 5 min.  PCR 
products were run on 2% agarose gels stained with ethidium bromide.  Densitometry was 
performed on the gels using Image J.  The mRNAs of interest were normalized to the 
housekeeping genes.  
 
Table 5.  Primers 
Gene Forward Primer (5’-3’) Reverse Primer (5’-3’) 
VEGFA CTTGCCTTGCTGCTCTACCT GCAAGGCCCACAGGGATTTT 
MT2A CAACCTGTCCCGACTCTAGC TGGAAGTCGCGTTCTTTACAT 
Mt1 CACCAGATCTCGGAATGGAC AGGAGCAGCAGCTCTTCTTG 
RPL13A  CGAGGTTGGCTGGAAGTACC ATTCCAGGGCAACAATGGAG 
β-actin GGGACCTGACCGACTACCTC GGGCGATGATCTTGATCTTC 
IRF7 TGTGGACACCTGTGACACCT GTTATCTCGCAGCATCACGA 
IRF1 TGCTAAGAGCAAGGCCAAGAG CGACTGCTCCAAGAGCTTCAT 
Irf7 CAGTTGATCCGCATAAGGTGT CTCGTAAACACGGTCTTGCTC 
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2.5 TRANSFECTIONS AND LUCIFERASE ASSAYS 
2.5.1 Transformation of DH5α™ competent cells and plasmid preparation 
The plasmid was mixed with 50 µl of DH5α competent cells and incubated on ice for 30 min.  
The mixture was heat shocked for 45 s at 42°C to allow the plasmid to enter the bacteria.  The 
cells were incubated on ice for 2 min before 900 µl of LB Broth (Table 3) was added.  The cells 
were shaken at 37°C for 1 h and cultured on plates containing the specific antibiotic to which the 
plasmid conferred resistance.  After incubating overnight at 37°C, one colony was selected and 
allowed to grow in LB broth containing the specific antibiotic for the plasmid.  DNA was 
isolated using either QIAGEN Plasmid Mini Kit or EndoFree Plasmid Maxi Kit (Qiagen Inc., 
Valencia, CA). 
2.5.2 Transient Transfection 
2.5.2.1 BEAS-2B Cell Transfection 
BEAS-2B cells (70-80% confluence) were transfected with the luciferase reporter constructs 
(Table 6) using Lipofectamine and PLUS reagents (Invitrogen) in 12-well plates.  Briefly, 1 µg 
of plasmid DNA was incubated with 4.2 µl of PLUS reagent in 100 µl of LHC-9 media for each 
well for 15 min at room temperature.  After the incubation period, 2.8 µl of lipofectamine 
reagent diluted in 100 µl of LHC-9 media per well was added to the plasmid DNA mixture and 
incubated for an additional 15 min.  200 µl of the transfection reagent was added to each well 
containing 300 µl of fresh LHC-9 medium.  3-4 h after the transfection, an additional 500 µl of 
LHC-9 medium was added to each well.  After an overnight recovery period, cells were treated.  
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Cells were co-transfected with pRL-TK or eGFP plasmids for normalizing transfection 
efficiency. 
2.5.2.2 MEF Cell Transfection 
MEF cells were transiently transfected as described above with the BEAS-2B cells except for the 
following adjustments.  Cells were transfected with the control or Fyn-Myc expression plasmid 
(Table 6) in 12-well plates for RNA and total protein or 6-well plates for nuclear protein.  2 µg 
or 4 µg of plasmid DNA was incubated with PLUS reagent in 100 or 250 µl of Opti-MEM® I 
Reduced-Serum Medium (Invitrogen) for 12-well or 6-well plates, respectively.  The transfection 
reagent was added to each well containing fresh DMEM supplemented with 10% FBS, 4 mM L-
glutamine, and 1% penicillin/streptomycin.  The next day the medium was replaced with DMEM 
supplemented with 0.1% BSA instead of 10% FBS.  Cells were treated 48 h after the transfection 
for optimal expression of the plasmid. 
2.5.3 Luciferase Assay 
Luciferase assays were performed using the Dual-Luciferase® Reporter Assay System 
(Promega, Madison, WI) in experiments that were co-transfected with pRL-TK.  Briefly, cells 
were rinsed twice and scraped in 1 ml of cold PBS and centrifuged at 13,000g for 3 min at 4°C.  
The pellet was resuspended in 50 µl of the lysis buffer provided and centrifuged at 13,000g for 5 
min at 4°C.  The supernatant was transferred to 12 X 50 polypropylene tubes (Turner Designs, 
Sunnyvale, CA) and 50 µl of Luciferase Assay Reagent II was added and firefly luciferase 
activity was determined.  50 µl of Stop & Glo® Reagent was added to quench the firefly 
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luciferase signal and initiate Renilla luciferase activity.  Results are expressed as a ratio of firefly 
luciferase activity to Renilla luciferase activity.   
Cells co-transfected with eGFP were harvested in 80 µl of lysis buffer (Table 3) and 
centrifuged at 13,000g for 5 min at 4°C.  The supernatant was transferred to 12 X 50 
polypropylene tubes and 120 µl of luciferase assay buffer was added.  The tube was placed in a 
TD-20/20 luminometer (Turner Designs) and 50 µl of luciferin was added.  The RLU were 
determined for 20 s.  RLU were normalized to GFP fluorescence measured using a fluorescent 
plate reader (ex 485 nm, em 508 nm). 
2.6 REACTIVE OXYGEN SPECIES (ROS) MEASUREMENTS 
ROS were detected using 5-(and-6)-chloromethyl-2’7’-dichlorodihydrofluorescein diacetate, 
acetyl ester (CM-H2DCFDA) (Invitrogen).  Cells were seeded in a 24 well plate and 
preincubated with NAC or AA.  Cells were incubated (37°C; 10 min) with CM-H2DCFDA (20 
µM) and exposed to Ni (10 min).  Fluorescence was read using a fluorescent plate reader 
(excitation (485 nm) emission (530 nm)).   
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Table 6.  Plasmids 
Plasmid Description Origin 
eGFP-MTF-1 enhanced green fluorescent 
protein (eGFP) fused to the N-
terminus of MTF-1 
B.R. Pitt (139) 
pLucMRE luciferase reporter construct 
driven by 4 MRE tandem 
repeats 
D. Giedroc (140) 
 pRL-TK  Renilla luciferase reporter 
construct containing the 
herpes simplex virus 
thymidine kinase promoter 
region 
Promega (Madison, WI) 
HRE-luc   Luciferase reporter construct 
driven by 3 HRE tandem 
repeats 
K. Salnikow (141) 
Sp1-luc Luciferase reporter construct 
driven by Sp1 
K. Salnikow (141) 
eGFP-N2 Enhanced green fluorescent 
protein 
BD Biosciences 
ISRE-luc luciferase reporter construct 
driven by ISRE 
Mercury™ JAK/STAT 
Pathway Profiling System, BD 
Biosciences 
GAS-luc luciferase reporter construct 
driven by GAS 
Mercury™ JAK/STAT 
Pathway Profiling System, BD 
Biosciences 
Fyn-myc Fyn expression vector L.M.  Zubritsky and A.A. 
Nemec 
pcDNA™ 3.1/myc-His(-) C Expression vector Invitrogen 
 
2.7 FLOW CYTOMETRY 
Cells were incubated (37°C; 1 h) with 5 µM free Zn fluorophore FluoZin-3™ AM ester 
(Invitrogen) with Pluronic F-127 (equal volume) (Invitrogen) in HBSS containing calcium and 
magnesium (Invitrogen).  Cells were then rinsed with HBSS and treated (30 min) with pyrithione 
in the presence or absence of either 20 µM Ni or 10 µM Zn.  TPEN (50 µM) was added (5 min) 
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to chelate the free Zn.  Cells were rinsed in PBS, trypsinized, and centrifuged at 1000g for 10 
min.  The pellet was resuspended with PBS containing 100 µg/ml propidium iodide (Sigma-
Aldrich) and incubated (37°C; 1 h) in the dark to stain dead cells.  Flow cytometry was 
performed using a FACSCanto (BD Biosciences, San Jose, CA).     
2.8 CONSTRUCTION OF THE FYN EXPRESSION VECTOR (FYN-MYC) 
The c-Fyn cDNA from pRK5 c-Fyn (Addgene, Inc, Cambridge, MA) was subcloned into 
pcDNA 3.1/myc-His(-)C (Invitrogen) using BamHI and HindIII sites.  The insert was separated 
on a 1% agarose gel stained with ethidium bromide and the DNA was isolated using the 
QIAquick Gel Extraction Kit (Qiagen Inc.).  The c-Fyn cDNA was ligated with the linearized 
pcDNA 3.1/myc-His(-)C using T4 DNA ligase (Stratagene La Jolla, CA).  The ligation was 
transformed and the resultant clones were sequenced at the Genomics and Proteomics Core 
Laboratories at the University of Pittsburgh to verify the presence of c-Fyn cDNA. 
2.9 LENTIVIRAL SHRNA TRANSDUCTION 
BEAS-2B cells were seeded at 50% confluence in 6 well plates.  After the cells were allowed to 
attach overnight, they were transduced with GFP-expression control and Fyn shRNAs.  The 
GFP-expression control and 5 Fyn shRNAs were designed and prepared by the Lentiviral Core 
Facility at the University of Pittsburgh Cancer Institute.  Briefly, 1 ml of LHC-9 media was 
combined with 1 ml of the specific virus (106 infectious units per ml) and 2 µl polybrene and was 
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added to each individual well.  Cells were incubated overnight and fresh media was given the 
following day.  The cells were analyzed for GFP expression and protein knockdown 3 days after 
transduction.   
2.10 CELL VIABILITY ASSAY 
The viability of cells following experimental exposures was examined using the Alamar Blue™ 
assay (Alamar Biosciences, Inc., Sacramento, CA) according to manufacturer’s instructions.  
Following exposure, 50 µl of alamar blue was added to each well of a 24-well plate and 
incubated at 37°C for an additional 3 h.  Absorbance was measured at 570 nm and 600 nm in a 
microplate reader.   
2.11 STATISTICS 
One-way analysis of variance (ANOVA) or two-way ANOVA were used as appropriate to 
determine whether the mean of each treatment was different from the untreated cells.  Dunnett’s 
or Tukey’s Multiple Comparisons post hoc tests were used to determine significant differences 
between the means of each group.  Linear trend analysis was performed to determine if there was 
a time-dependent response.  All statistics were performed using GraphPad Prism version 5 
(GraphPad Software, San Diego, CA).  Data are represented as mean ± SEM or as fold control. 
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3.0  CHROMIUM(VI)-ACTIVATED SIGNAL TRANSDUCER AND ACTIVATOR OF 
TRANSCRIPTION 1 (STAT1) SIGNALING IS MEDIATED BY FYN 
3.1 ABSTRACT 
Mechanisms for metal signaling in the molecular pathogenesis of airway injury or diseases are 
poorly understood. We previously reported that chromium (Cr(VI)) represses induction of repair 
genes by activating signal transducer and activator of transcription 1 (STAT1).  In the current 
study, we investigated the hypothesis that Cr(VI) activates the Src family kinase (SFK), Fyn, to 
activate STAT1 and stimulate STAT1-dependent gene induction in human airway epithelial 
(BEAS-2B) cells.  Cr(VI) selectively stimulated transactivation of STAT1 responsive interferon-
stimulated response element (ISRE) and induced ISRE-driven interferon regulatory factor 7 
(IRF7), without affecting the gamma interferon-activated site (GAS)-driven IRF1.  Cr(VI)-
induced IRF7 was absent in cells stably expressing STAT1 shRNA or cells treated with sodium 
butyrate indicating requirements for both STAT1 and histone deacetylase (HDAC) activity.  In 
contrast, Cr(VI)-activated ISRE was not blocked in cells incubated with a neutralizing antibody 
to interferon α/β receptor indicating that Cr(VI) signaling was independent of interferon 
signaling.  Cr(VI) activation of STAT1 signaling was diminished in mouse embryonic fibroblasts 
null for the SFKs, Src, Yes, and Fyn.  However, expressing Fyn, but not Src in these deficient 
cells restored the Cr(VI) response indicating that Fyn was required for Cr(VI)-stimulated 
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STAT1.  Cr(VI) activated Fyn in BEAS-2B cells and the activation of STAT1-dependent 
signaling was abrogated in cells expressing Fyn shRNA   These data presents a novel mechanism 
through which Cr(VI) initiates interferon-like signaling by activating Fyn to stimulate STAT1-
dependent transactivation and repression of airway epithelial cell genes.   
3.2 INTRODUCTION 
Chromium is a well-known environmental pollutant known to promote airway diseases.  Several 
million people world-wide are exposed to Cr(VI) and Cr(VI)-containing compounds (6).  
Chronic inhalation of Cr(VI) causes pulmonary diseases such as chronic bronchitis, asthma, 
emphysema, and cancers through poorly defined mechanisms (13,42,47).  Cr(VI) exists as a 
chromate oxyanion under physiological conditions and, unlike Cr(III), can readily enter the cell 
through anion channels (5,9).  Once Cr(VI) enters an airway cell, greater than 90% is trapped 
within the cell through reduction by ascorbate or glutathione to Cr(III) (9,10).  These one-way 
kinetics reduce Cr clearance and make the epithelium lining of the airways the main target of 
inhaled Cr(VI) (11).   
Signal transducers and activators of transcription (STAT) are a family of latent 
cytoplasmic transcription factors.  There are seven different members that are activated 
by exogenous stresses (64-66), including metals (55), to produce diverse biological 
responses.  STAT proteins are activated through phosphorylation on a conserved tyrosine 
residue in the C-terminus, followed by dimerization, and translocation into the nucleus (52).  
Non-receptor tyrosine kinases (NRTKs) such as Janus kinases (JAKs) and Src family kinases 
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(SFKs) are involved in phosphorylating the STAT proteins to initiate STAT-dependent signaling 
(52,55,142,143). We have previously shown that Cr(VI)-activates both STAT1 and STAT3 in 
airway epithelium and that prolonged STAT3 activation required the SFK, Lck (55).   
STAT1 was originally identified as a downstream effector of interferon (IFN) signaling 
(57) and is required to induce antiviral and antiproliferative responses (67,68).  Once 
phosphorylated, STAT1 forms either a homodimer that binds to IFNγ activation sites (GAS) to 
transcribe GAS-driven genes (e.g. interferon regulatory factor (IRF 1)) or a heterotrimeric 
complex, interferon-stimulated gene factor 3 (ISGF3), with STAT2 and IRF9 and bind to 
interferon-stimulated response elements to transcribe ISRE-driven genes (e.g. IRF7) (57).  Type 
I IFNs (e.g. IFN-α2) and type II IFNs (e.g. IFN-γ) signal through cell surface receptors to 
activate STAT1.  Type I IFNs induce the formation of STAT1 homodimers and STAT1 and 
STAT2 heterodimers, whereas type II IFNs induce only the formation of STAT1 homodimers 
(144).  Histone deacetylase (HDAC) binding to the ISGF3 complexes and its enzymatic activity 
are required to recruit RNA polymerase II to the promoter for STAT1 activation of ISRE-, but 
not GAS-, driven genes (61,145).   
STAT1 activation promotes apoptosis in cardiac myocytes after ischemia and reperfusion 
(64) and has also been implicated in the pathogenesis of lung diseases (70).  STAT1 activation 
was localized to the bronchial epithelial cells in asthmatic patients (1) suggesting that aberrant 
expression of STAT1 may be a precursor to disease.  In addition, type II IFN therapies to kill 
tumor cells fail in cancers that lack STAT1 (67,146) demonstrating the important suppressive 
role of the transcription factor.  We have previously reported that Cr(VI) stimulated the acute 
activation of STAT1 in human airway epithelial cells and STAT1-dependent repression of 
inducible genes.  In the current study, we sought to determine the mechanism through which 
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Cr(VI) initiated STAT1 signaling to provide insight into how Cr(VI) exerts pathological effects 
on the airway epithelium. 
3.3 RESULTS 
3.3.1 Cr(VI) selectively activates ISRE-dependent STAT1 signaling. 
We have previously reported that Cr(VI) induces the tyrosine phosphorylation and nuclear 
translocation of STAT1 within 4 h in BEAS-2B cells (55).  Upon activation, STAT1 can form 
homodimers or heterodimers that bind to GAS and ISRE consensus sequences, respectively, to 
induce gene transcription (57).  Using luciferase constructs driven by these sequences, it was 
determined that exposure to Cr(VI) results in ISRE, but not GAS transactivation (Fig. 11 and 
data not shown).  Similarly, Cr(VI) induced the ISRE-driven gene, IRF7, and had no effect on 
GAS-driven IRF1 (Fig. 11).   
3.3.2 STAT1 is required for Cr(VI) activation of ISRE.   
To confirm the requirement for STAT1 in the Cr(VI)-stimulated ISRE transactivation, BEAS-2B 
cells stably expressing random (shNC) or STAT1-specific (shSTAT1) shRNA were exposed to 
Cr(VI).  Western analysis verifies the knockdown of STAT1 in the shSTAT1 cells compared to 
shNC cells (Fig 12A).  Cr(VI) activated ISRE and induction of IRF7 mRNA expression in the 
shNC cells.  However, this response was lost in the shSTAT1 cells (Fig. 12B-C) indicating the 
necessity of STAT1 in the response to Cr(VI). 
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Figure 11.  Cr(VI) stimulates ISRE-, but not GAS-dependent transactivation. 
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A-B.  BEAS-2B cells were exposed to Cr(VI) for indicated times and total RNA was isolated.  IRF7 and 
IRF1 mRNA levels were measured by RT-PCR and real-time PCR, respectively, and normalized against the 
housekeeping gene, RPL13A.  C.  BEAS-2B cells were transfected with the ISRE-luc reporter construct.  After 24 h, 
cells were treated with 5 μM Cr(VI) or 100 U/ml IFN-α2 for 4h.  Cell lysates were analyzed for luciferase activity.    
Data are presented as mean ± SEM of fold control (n=3).  * and *** designate p<0.05 and  p<0.001, respectively. 
 
 
Figure 12.  Cr(VI) induction of IRF7 mRNA requires STAT1. 
A.  Total protein was isolated from BEAS-2B cell lines stably expressing either random (shNC) or STAT1 
(shSTAT1) shRNA and total STAT1 and β-actin protein levels were determined by western analysis.  B.  shNC 
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(open bars) and shSTAT1 (closed bars) cells were exposed to 5 µM Cr(VI) for 0, 1, and 4 h.  Total RNA was 
isolated and IRF7 mRNA was measured by RT-PCR and normalized to the housekeeping gene, RPL13A.  C.  shNC 
(open bars) and shSTAT1 (close bars) cells were transiently transfected with the ISRE-luc reporter construct.  After 
24 h, cells were exposed to 5 µM Cr(VI) for 4 h and luciferase activity was measured.  Data are presented as mean ± 
SEM of fold control (n=3).  * and *** designate p<0.05 and  p<0.001, respectively, compared to untreated (control) 
cells.  ^ and ^^^ designate p<0.05 and p<0.001, respectively, compared to the shNC cells at the same time point. 
3.3.3 HDAC activity is required for Cr(VI) induction of IRF7.   
Cr(VI) inhibits polycyclic aromatic hydrocarbon (PAH)-induced gene induction by retaining 
HDAC in their proximal promoters (24).  In contrast, HDAC activity is required to recruit RNA 
polymerase to the promoter of ISRE-driven genes (61).  To examine the necessity of HDAC for 
Cr(VI) induction of IRF7, BEAS-2B cells were pretreated with the global HDAC inhibitor, 
sodium butyrate (NaB), before exposure to Cr(VI).  Cr(VI) had no effect on ISRE transactivation 
levels in cells pretreated with NaB compared to vehicle-treated cells (Fig. 13) suggesting that 
HDAC activity is essential for Cr(VI) activation of ISRE and IRF7 induction. 
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Figure 13.  H DAC ac tivity i s n ecessary f or C r(VI)-stimulated I SRE t ransactivation an d I RF7 
induction. 
A.  BEAS-2B cells were exposed to 5 µM Cr(VI) for 4 h after a 16 h pretreatment with 2 mM NaB and 
total RNA was isolated.  IRF7 mRNA levels were measured by RT-PCR and normalized against the housekeeping 
gene, RPL13A.  B.  BEAS-2B cells were transfected with the ISRE-luc reporter construct.  After 24 h, cells were 
pretreated with 2 mM sodium butyrate for 16 h followed by treatment with 5 μM Cr(VI) for 4 h.  Cell lysates were 
analyzed for luciferase activity.  Data is presented as mean ± SEM of fold control (n=3).  * and ** designate p<0.05 
and p<0.01, respectively, compared to untreated (control) cells.  ^ and ^^^ designate p<0.05 and p<0.001, 
respectively, compared to cells treated with Cr(VI) alone. 
3.3.4 Cr(VI) transactivation of ISRE is independent of type I interferon signaling. 
Type I IFNs bind to the type I IFN receptor to stimulate STAT1 and STAT2 tyrosine 
phosphorylation and subsequent dimerization (52,59).  To determine if Cr(VI) was also signaling 
through this receptor, a neutralizing antibody against one of the 2 subunits of the receptor 
(IFNAR) was added to cells prior to Cr(VI) treatment.  Whereas the IFN-α2 induction of IRF7 
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was abrogated in cells treated with the neutralizing antibody, no effect was observed in the 
Cr(VI)-treated cells (Fig. 14).  These data indicate that Cr(VI) signaling for IRF7 induction is 
independent of type I IFN signaling.   
 
 
Figure 14.  Cr(VI) induction of IRF7 mRNA is independent of type I IFN signaling. 
BEAS-2B cells were treated with IFNAR, a neutralizing antibody for the IFN-α/β receptor, for 30 min prior 
to treatment with 5 µM Cr(VI) or 100 U/ml IFN-α2.  Total RNA was isolated and IRF7 mRNA levels were 
measured by RT-PCR and normalized against the housekeeping gene, RPL13A.  Data is presented as means ± SEM 
of fold control.  ** and *** designate p<0.01 and p<0.001, respectively, compared to the respective untreated 
(control) cells.  ^^^ designates p<0.001 compared to cells treated with IFN-α2 alone. 
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3.3.5 Cr(VI)-activated STAT1 signaling requires Fyn. 
We previously reported that Cr(VI) activates both Fyn and Lck, but not Src or Yes in airway 
cells (22).  In addition, we demonstrated that Cr(VI)-stimulated STAT3 translocation and 
induction of interleukin-6 (IL-6) mRNA transcription required Lck activity (55).  In keeping with 
the previous observation made in A549 cells, Cr(VI) activated Fyn within 15 min of exposure in 
the BEAS-2B cells (Fig. 17A-B). Incubating the BEAS-2B cells with the global SFK inhibitor 
PP2 blocked Cr(VI)-activated STAT1 and the induction of IRF7 transcription (Fig. 15A-C) 
indicating a role for SFK in the STAT1-dependent response.  STAT1 was activated by Cr(VI) in 
wildtype MEF cells (Fig 15D-F).  However, there was no Cr(VI) response in Src, Yes, and Fyn 
(SYF) null MEF cells or in (Src++) MEF cells lacking only Yes and Fyn  (Fig. 15D-F).  In 
contrast, transiently transfecting SYF cells with human Fyn restored Cr(VI)-stimulated STAT1 
signaling (Fig. 16).  The overexpression of Fyn was verified by western analysis and it should be 
noted that the antibody used only recognized human Fyn (Fig. 16A).  In reciprocal experiments, 
BEAS-2B cells were transduced with GFP-expression control and Fyn lentiviral shRNA.  The 
knockdown of Fyn was verified by western analysis (Fig. 17C).  Cr(VI)-activated STAT1 and 
induction of IRF7 was inhibited in BEAS-2B cells expressing Fyn shRNA compared to the 
control shRNA cells (Fig. 17D-F).  These data indicate that Cr(VI)-activated Fyn mediates the 
phosphorylation of STAT1 and induction of IRF7 mRNA expression. 
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Figure 15 continued below. 
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Figure 15.  Cr(VI) activation of STAT1 requires Src family kinases. 
A.  BEAS-2B cells were pretreated with PP2 for 30 min prior to the addition of 5 µM Cr(VI) for 1 h.  
pYSTAT1, STAT1, and β-actin levels were determined by western analysis and a representative blot from a single 
experiment is shown.  B.  Density of the protein bands from three separate experiments were quantified with ImageJ 
software.  C.  BEAS-2B cells were pretreated with PP2 for 30 min prior to the addition of 5 µM Cr(VI) for 4 h.  
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Total RNA was isolated and IRF7 mRNA levels were measured by RT-PCR and normalized against the 
housekeeping gene, RPL13A.  D.  Wild-type (WT), SYF, and Src++ MEF cells were incubated with 5 µM Cr(VI) 
for the indicated times and nuclear protein was isolated.  pYSTAT1, total STAT1, and β-actin levels were 
determined by western analysis and a representative blot from a single experiment is shown.  E.  Density of the 
protein bands from three separate experiments were quantified with ImageJ software.  F.  WT, SYF, and Src++ 
MEF cells were exposed to 5 µM Cr(VI) for the indicated times and total RNA was isolated.  Irf7 mRNA levels 
were measured by RT-PCR and normalized to the housekeeping gene, β-actin.  Data is presented as mean ± SEM of 
fold control (n=3).  * and *** designate p<0.05 and  p<0.001, respectively, compared to untreated (control) cells.  ^ 
and ^^^ designate p<0.05 and  p<0.001, respectively, compared to cells treated with Cr(VI) alone.   
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 Figure 16 continued below. 
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Figure 16.  Fyn mediates Cr(VI)-activated STAT1 signaling in MEF cells. 
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Wildtype and SYF MEF cells were transiently transfected with either the control vector or the Fyn-myc 
expression vector.  A.  Total protein was isolated and Fyn and β-actin protein levels were determined by western 
analysis.  B.  Cells were treated with 5 µM Cr(VI) for 2 h and nuclear protein was isolated.  pYSTAT1, total 
STAT1, and β-actin levels were determined by western analysis and a representative blot from a single experiment 
is shown.  C.  Density of the protein bands from three separate experiments were quantified with ImageJ software.  
D.  Cells were treated with 5 µM Cr(VI) for 4 h and total RNA was isolated and Irf7 mRNA levels were measured 
by RT-PCR and normalized to the housekeeping gene, β-actin.  Data is presented as mean ± SEM of fold control.  * 
designates p<0.05 compared to respective untreated (control) cells.   
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Figure 17.  Fyn is required for Cr(VI) activation of STAT1 in BEAS-2B cells. 
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A.  BEAS-2B cells were exposed to 5 µM Cr(VI) and total Fyn was immunoprecipitated from whole cell 
lysates and immunoblotted for pFyn and total Fyn.  A representative blot from a single experiment is shown.  B.  
Density of the protein bands from three separate experiments were quantified with ImageJ software.  C-F.  BEAS-
2B cells were transduced with GFP-expression control or Fyn shRNA.  C.  Total protein was isolated and Fyn and 
β-actin protein levels were determined by western analysis.  D.  Cells were exposed to 5 µM Cr(VI) for 1 h and 
nuclear protein was isolated.  pYSTAT1, total STAT1, and β-actin levels were determined by western analysis and a 
representative blot from a single experiment is shown.  E.  Density of the protein bands from three separate 
experiments were quantified with ImageJ software.  F.  Cells were exposed to 5 µM Cr(VI) for 4 h and total RNA 
was isolated and Irf7 mRNA levels were measured by RT-PCR and normalized to the housekeeping gene, RPL13A.  
Data is presented as mean ± SEM of fold control.  *, **, and *** designate p<0.05, p<0.01, and p<0.001, 
respectively, compared to respective untreated (control) cells. ^^ designates p<0.01 compared to GFP-expression 
control-transfected cells.   
3.4 DISCUSSION 
Cr(VI) is a well known environmental and occupational hazard known to promote pulmonary 
diseases (6,13,42,47).  However, the mechanisms of Cr(VI)-induced pulmonary diseases remain 
unresolved.  The data in this study demonstrated that non-cytotoxic concentrations of Cr(VI) 
activated STAT1-dependent gene signaling and transactivation in airway epithelial cells.  In 
addition, the SFK, Fyn, was identified as mediating Cr(VI)-stimulated STAT1. STAT1 
activation can contribute to the development of pulmonary inflammatory diseases and its actions 
are localized to the airway epithelium (1), a target of Cr(VI) toxicity (11).  Thus these novel 
findings may reveal mechanistic understanding of the molecular pathogenesis of Cr(VI)-induced 
lung diseases. 
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The current data and our previous report (55), demonstrate that airway epithelial cell 
exposure to Cr(VI) increases the transcriptional activation of members of the STAT family,  
including STAT1 and STAT3.  STATs are activated through the phosphorylation of a conserved 
tyrosine residue in the C-terminus by JAKs or SFKs (52,55,142,143).  We have previously 
demonstrated that the prolonged stimulation of STAT3 was mediated by the SFK, Lck (55).  
SFK activity was also involved in Cr(VI)-activated STAT1 signaling since pretreatment of cells 
with the SFK, PP2, prevented STAT1 activation and IRF7 induction (Fig. 5A-C).  Cr(VI) 
stimulation of STAT1 was attenuated in MEF cells null for Src, Yes, and Fyn (SYF) suggesting 
that Cr(VI) was activating one or more of these kinases (Fig. 5D-F).  However, Cr(VI) only 
stimulated Fyn, and not Src or Yes, in A549 cells and directly activated affinity purified Fyn in 
vitro (22).  Similarly, Cr(VI) stimulated the phosphorylation of Fyn in BEAS-2B cells (Fig. 7A-
B).  Furthermore, Cr(VI)-activated STAT1 and induction of Irf7 mRNA expression in SYF cells 
transiently transfected with human Fyn cDNA (Fig. 6B-D) indicating that Cr(VI) stimulates 
STAT1-dependent signaling through the activation of Fyn.  Moreover, the Cr(VI) was lost in 
BEAS-2B cells transduced with Fyn shRNA compared to control cells (Fig. 7D-F).  However, 
the mechanism for the increase in the catalytic activity of Fyn is unclear.  There are 2 critical 
cysteine residues flanking 10 amino acids in the C-terminal lobe of several members of the SFKs 
that can bind metals to induce a conformational change (74).  The effect of Cr(VI) on the binding 
to these cysteines has not been investigated, but remains an area of interest.  Also, Fyn may not 
be directly activating STAT1 since both Fyn and Src phosphorylate another NRTK, c-Abl (147), 
which has been demonstrated to phosphorylate STAT1 (148,149) and is an indirect target of PP2.   
However, despite a possible intermediate step, the data indicate that activation of Fyn is the 
initial target of Cr(VI) signaling.   
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Activated STAT1 forms homodimers or heterotrimers with STAT2 and IRF9 in the 
ISGF3 complex to bind to GAS or ISRE consensus sequences, respectively (57).  Cr(VI) 
selectively activated ISRE-driven transcription and had no effect on GAS transactivation (Fig. 
1).  Cr(VI)-stimulated ISRE transactivation and IRF7 mRNA induction was attenuated in BEAS-
2B cells stably expressing STAT1 shRNA (Fig. 2), thus confirming the requirement of STAT1.  
IFN-mediated signaling is the most characterized pathway for STAT1 activation.  Type I IFNs, 
such as IFN-α2, bind the cell surface type I IFN receptor to activate kinases to phosphorylate 
STAT1 (52,59).  However, the signaling events activated by Cr(VI) are independent of type I 
IFN signaling since blocking IFNAR subunit of the receptor with a neutralizing antibody did not 
affect Cr(VI)-induced IRF7, but did prevent the IFN-α2 induction of the gene (Fig. 4).  The 
negative control, normal mouse IgG antibody, had no effect indicating that the results observed 
were due to interfering with type I IFN-mediated signaling and not a nonspecific response (data 
not shown).   
Although histone deacetylation is correlated with gene repression, HDAC activity is 
required for induction of ISRE-driven genes by facilitating the recruitment of RNA polymerase 
II to the promoter (61).  HDAC activity is required for Cr(VI)-induced IRF7 transcripts since 
pre-incubating cells with NaB, a HDAC inhibitor, prevented both ISRE transactivation and IRF7 
induction (Fig. 3).  Interestingly, Cr(VI) suppresses the induction of AHR receptor-transactivated 
genes by preventing HDAC release from their proximal promoters and interfering with the 
assembly of the transcriptional machinery (24).   
In summary, the present study demonstrated that Cr(VI) activates STAT1 to form the 
ISGF3 complex and induce IRF7 mRNA expression.  This activation is independent of type I 
interferon signaling, but is mediated by Fyn.  STAT1 is a primary regulator of antiproliferative 
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and apoptotic responses (67,68) and plays a role in the pathogenesis of inflammatory lung 
diseases (1).  Thus, these findings may provide critical insight into the mechanism of the 
development of Cr(VI)-related pulmonary diseases.    
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4.0  SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) 
IS ESSENTIAL FOR CHROMIUM SILENCING OF GENE INDUCTION IN HUMAN 
AIRWAY EPITHELIAL CELLS 
The data presented in this chapter is published in Toxicol Sci 2009 Apr 29 [Epub ahead of print]. 
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4.1 ABSTRACT 
Cr(VI) promotes lung injury and pulmonary diseases through poorly defined mechanisms that 
may involve the silencing of inducible protective genes. The current study investigated the 
hypothesis that Cr(VI) actively signals through a STAT1-dependent pathway to silence Ni-
induced expression of VEGFA, an important mediator of lung injury and repair. In human 
bronchial airway epithelial (BEAS-2B) cells, Ni induced VEGFA transcription by stimulating an 
ERK signaling cascade that involved Src kinase-activated Sp1 transactivation, as well as 
increased HIF-1α stabilization and DNA binding.  Ni-stimulated ERK, Src, and HIF-1α 
activities, as well as Ni-induced VEGFA transcript levels were inhibited in Cr(VI) exposed cells.  
We previously demonstrated that Cr(VI) stimulates STAT1 to suppress VEGFA expression.  In 
BEAS-2B cells stably expressing STAT1 shRNA, Cr(VI) increased VEGFA transcript levels and 
Sp1 transactivation.  Moreover, in the absence of STAT1, Cr(VI) and Ni co-exposures positively 
interacted to further increase VEGFA transcripts.  This study demonstrates that metal-stimulated 
signaling cascades interact to regulate transcription and induction of adaptive or repair responses 
in airway cells.  In addition, the data implicate STAT1 as a rate limiting mediator of Cr(VI)-
stimulated gene regulation and suggest that cells lacking STAT1, such as many tumor cell lines, 
have opposite responses to Cr(VI) relative to normal cells. 
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4.2 INTRODUCTION 
Chronic inhalation of Cr(VI) and Ni are well known environmental and occupational hazards 
that promote pulmonary diseases (42,43,150).  Mixed exposures are common in metal industries 
(37,42,47) and human epidemiological studies have associated mixed exposures with increased 
risks of lung diseases compared to exposure to the individual metals (37,42,47-49).  However, 
there is limited mechanistic understanding of the cellular and molecular pathogenic actions of the 
individual metals or their interactions in airway epithelial cell injury and repair processes.   
VEGFA expression is well-established in vascular biology for its role in angiogenesis and 
vascularization.  However, its role in the airway epithelium and lung injury repair remains 
unclear.  Epithelial cells are the major source of VEGFA in the lung (99) and VEGFA is crucial 
for normal lung development (99) and airway epithelial cell proliferation (102).  Yet, its role in 
lung injuries and disease remains controversial (106).  Elevated VEGFA promotes pulmonary 
edema in the initial phase of inflammatory diseases, such as asthma, chronic bronchitis, and ALI 
(105,106).  However, in later phases, increased VEGFA levels are associated with the resolution 
of ALI (114).  VEGFA levels are decreased in patients with bronchopulmonary dysplasia, 
emphysema, and during ischemia and reperfusion correlating to epithelial cell damage (105,108).  
Moreover, in both in vivo skin and in vitro lung epithelial cell models, VEGFA promotes wound 
repair and elicits anti-apoptotic responses (113,115). 
The main inducers of VEGFA expression are hypoxia (151) and other stimuli that 
stabilize HIF-1α, which transactivates the VEGFA promoter (116).  These stimuli include a 
variety of metals, including Ni (118,119,122,141).  Ni stabilizes HIF-1α primarily by direct 
inhibition of the prolyl hydroxylases that mark HIF-1α for proteosomal degradation (122).  
However, Ni can also signal through ERK and PI3K to increase both HIF-1α stability and its 
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transactivation of genes (118,119).  HIF-1α cooperates with other transcription factors (e.g. Sp1, 
activator protein 1 (AP-1), STAT3) (124-126) and Sp1 transactivation is required for full 
induction of the VEGFA promoter (129).  Unlike STAT3, STAT1, stimulated by IFN, is a 
negative regulator of VEGFA (68) and the loss of STAT1 results in IFN stimulating 
transcriptional activation of the VEGFA promoter (146,152).  Once STAT1 is activated, it forms 
the complex, ISGF3 which inhibits IFN-β-stimulated genes by interfering with the assembly of 
the transcriptional machinery on the promoters (62,63).  
Exposure to Cr(VI) silences the induction of protective genes induced by polycyclic 
aromatic hydrocarbons and metals by activating signaling pathways that alter transcriptional 
activity (19,24).  We previously reported that Cr(VI) stimulates STAT1 phosphorylation and 
nuclear translocation in human airway epithelial cells (55).  Therefore, the current studies 
examined the hypothesis that Cr(VI) suppresses Ni-induced VEGFA expression by stimulating 
STAT1-dependent gene repression.  
4.3 RESULTS 
4.3.1 Cr(VI) inhibits Ni-induced VEGFA mRNA and protein release 
Cr(VI) often suppresses gene inducibility, including induction of protective genes in the lung and 
metal-stimulated gene induction in cultured lung cells (19).  The data in Figure 18 are consistent 
with this observation and confirm that Cr(VI) represses both Ni-induced VEGFA mRNA and 
protein release in BEAS-2B cells, but has no effect on basal expression.  
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Figure 18.  Cr(VI) inhibits Ni-induced VEGFA mRNA and protein levels. 
BEAS-2B cells were exposed to 5 µM Cr(VI), 200 µM Ni, or Cr(VI) for 2 h prior to adding 200 µM Ni for 
A. 24 h and B. 48 h.  A.  VEGFA mRNA levels were measured by real-time PCR.  B.  Conditioned medium was 
collected and VEGF protein release was measured by ELISA.  Data represent means ± SEM of fold control (n=3).  
** and *** designate p<0.01 and p<0.001, respectively compared to untreated cells (control); ^^ and ^^^ designate 
p<0.01 and p<0.001, respectively compared to cells treated with Ni alone. 
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4.3.2 Ni induction of VEGFA mRNA requires ERK-dependent Src and HIF-1α 
activation 
To identify the mechanism for the negative interaction between Cr(VI) and Ni in the induction of 
VEGFA, we first characterized the Ni-stimulated signaling cascades leading to this induction.  
Ni activates both ERK- and HIF-1α signaling pathways in BEAS-2B cells (119) and both 
pathways are implicated in VEGFA transactivation (118,121,153).  To identify the role of the 
ERK relative to other kinases in Ni-induced VEGFA expression, BEAS-2B cells were pretreated 
with inhibitors of ERK (U0126), p38 (SB203580), PI3K (wortmannin), or SFK (PP2) prior to 
exposure to Ni.  Inhibition of ERK and SFK prevented Ni-induced VEGFA mRNA level 
whereas inhibiting p38 and PI3K had no effect (Figure 19A-B).  Note that there is no statistical 
difference between VEGFA transcript levels in the presence of Ni plus U0126 or PP2 relative to 
U0126 or PP2 alone.  This would suggest that the two inhibitors are equally effective in 
providing a complete or at least equal block of Ni-induced VEGFA.  ERK appeared to be 
upstream of SFK activation, since Ni-stimulated Src phosphorylation was absent in cells 
pretreated with U0126 (Figure 19C).  As demonstrated for Ni-induction of the SERPIN1 
promoter (119), ERK  was required for maximal Ni-stimulated HIF-1α stabilization and 
transactivation of VEGFA (Figure 20A).  In addition, Src was also found to be essential for Ni-
induction of the gene (Figure 19B), but not for Ni-stimulated HIF-1α stabilization (Figure 20B).  
These data indicate that both HIF-1α and Src are required for Ni-induced VEGFA mRNA 
expression and that they are divergent pathways downstream of ERK.  The VEGFA promoter 
contains numerous response elements that might be targets of ERK signaling, including Sp1 
(129,154,155).  A role for Sp1 in Ni-induced transactivation was demonstrated by Ni stimulating 
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the activity of a Sp1-driven luciferase reporter construct by 3.764 ± 0.6853 fold compared to 
untreated cells.  Together, these data suggest that the ERK-regulated pathways activated by Ni 
are both capable of functional gene activation that converge to induce the VEGFA promoter. 
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Figure 19.  ERK mediates Ni-induced VEGFA mRNA levels. 
BEAS-2B cells were pretreated with A.  10 µM U0126, 20 µM SB203580, or 1 µM wortmannin or B.  10 
µM PP2 prior to adding vehicle (white bars) or 200 µM Ni (black bars) for 24 h.  VEGFA mRNA levels were 
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measured by real-time PCR.  Data represent means ± SEM of fold control (n=3).  C.  BEAS-2B cells were 
pretreated with 10 µM U0126 prior to adding vehicle (white bars) or 200 µM Ni (black bars) for 30 min.  Total Src 
was immunoprecipitated from whole cell lysates and immunoblotted for pSrc.  ImageJ software was used to quantify 
the intensity of the bands and data represent means ± SEM of fold control (n=3).  ** and *** designate p<0.001 and 
p<0.001, respectively compared to untreated cells (control).  ^^^ designates p<0.001 compared to cells treated with 
Ni alone. 
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Figure 20.  Ni-induced HIF-1α stabilization requires ERK. 
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BEAS-2B cells were pretreated with A.  10 µM U0126, 20 µM SB203580, or 1 µM wortmannin or B. 10 
µM PP2 prior to adding vehicle (white bars) or 200 µM Ni (black bars) for 24 h.  Total protein was isolated and 
HIF-1α and β-actin protein levels were determined by western analysis.  ImageJ software was used to quantify the 
intensity of the bands.  Data represent means ± SEM of fold control (n=3).  *** designates p<0.001 compared to 
untreated cells (control); ^^^ designates p<0.001 compared to cells treated with Ni alone. 
4.3.3 Cr(VI) inhibits Ni-activated ERK signaling 
Exposure to Cr(VI) had no effect on the basal ERK or Src phosphorylation states (Figure 21), 
and Cr(VI) did not affect basal HIF-1α protein levels or the activity of a HRE-driven luciferase 
reporter construct (Figure 22).  In contrast, Cr(VI) inhibited Ni-stimulated ERK and Src 
activation (Figure 21), HIF-1α protein expression (Figure 22A), and transactivation of the HRE 
reporter construct (Figure 22B).  The pattern of inhibition is consistent with Cr(VI) preventing 
Ni from activating ERK, the upstream kinase of the divergent signaling pathways.  
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Figure 21.  Cr(VI) abrogates Ni-stimulated ERK signaling. 
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A.  BEAS-2B cells were exposed to 5 µM Cr(VI), 200 µM Ni, or Cr(VI) for 2h prior to adding 200 µM Ni 
for 5 min.  Total protein was isolated and phosphorylated ERK (pERK), total ERK, and β-actin protein levels were 
determined by western analysis.  B.  BEAS-2B cells were exposed to 5 µM Cr(VI), 200 µM Ni, or Cr(VI) for 2h 
prior to adding 200 µM Ni for 30 min.  Total Src was immunoprecipitated from whole cell lysates and 
immunoblotted for pSrc.  ImageJ software was used to quantify the intensity of the bands and data represent means 
± SEM of fold control (n=3).  ** and *** designate p<0.01 and p<0.001, respectively compared to untreated cells 
(control); ^^^ designates p<0.001 compared to cells treated with Ni alone. 
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Figure 22.  Cr(VI) partially inhibits Ni-induced HIF-1α stabilization and HRE transactivation. 
A.  BEAS-2B cells were exposed to 5 µM Cr(VI), 200 µM Ni, or Cr(VI) for 2 h prior to adding 200 µM Ni 
for 24 h.  Total protein was isolated and HIF-1α and β-actin protein levels were determined by western analysis.  
ImageJ software was used to quantify the intensity of the bands.  B.  BEAS-2B cells were transiently transfected 
with HRE-luc and eGFP.  After 24 h, cells were exposed to 5 µM Cr(VI), 200 µM Ni, or Cr(VI) for 2 h prior to 
adding 200 µM Ni for 8 h. Relative luciferase activity of HRE-luc was normalized to eGFP.  Data represent means ± 
SEM of fold control (n=3).   ** and *** designate p<0.01 and  p<0.001, respectively, compared to untreated cells 
(control); ^^ and ^^^ designate p<0.01 and p<0.001, respectively, compared to cells treated with Ni alone.   
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4.3.4 STAT1 signaling is essential for Cr(VI) repression of VEGFA 
STAT1 negatively regulates VEGFA induction (146) and transactivation by Sp1 (63).  To 
investigate a role for Cr(VI)-stimulated STAT1 in repressing VEGFA inducibility, we generated 
BEAS-2B cell lines stably expressing either scrambled (shNC) or STAT1 (shSTAT1) shRNA.  
Western blot analysis in Figure 23A verifies STAT1 protein knockdown in shSTAT1 cells 
relative to shNC cells.  In contrast to the response of parental BEAS-2B or the shNC cells, 
VEGFA mRNA levels increased in shSTAT1 cells within 4 h of Cr(VI) exposure (Figure 23C).  
In addition, a 2 h pretreatment of shSTAT1 cells with Cr(VI) enhanced VEGFA mRNA levels 
induced by Ni (Figure 23B) while the same treatment in shNC cells resulted in the same Cr(VI) 
inhibition of VEGFA inducibility observed in the parental BEAS-2B cells (Figure 18A and 23C).  
In addition, Cr(VI) had no effect on Ni-induced HIF-1α protein in the shSTAT1 cells relative to 
its effect in shNC cells (Figure 24A).  Finally, Cr(VI) increased the activity of the Sp1-driven 
luciferase reporter construct in shSTAT1 cells, whereas there was no Cr(VI) effect on luciferase 
activity in the shNC cells (Figure 24B).  The STAT1-containing complex, ISGF3, is known to 
indirectly inhibit IFN-β-inducible genes most likely by activating or increasing expression of an 
inhibitory protein (62,63). To examine this hypothesis that Cr(VI) stimulates ISGF3 induction of 
an inhibitor, parental BEAS-2B cells were exposed to Cr(VI) in the presence or  absence of 
cycloheximide to inhibit protein synthesis.  Data in Figure 23D confirm the effect of on basal 
VEGFA expression in control cells and demonstrates that Cr(VI) increased VEGFA mRNA 
levels when protein synthesis was inhibited.  These data suggest that Cr(VI) signals through 
STAT1 to repress VEGF mRNA expression and that STAT1 may exert its inhibitory effects by 
increasing expression of protein repressor of VEGFA induction.   
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Figure 23.  STAT1 is required for Cr(VI) suppression of VEGFA induction. 
A.  Total protein was isolated from BEAS-2B cell lines stably expressing either scrambled (shNC) or 
STAT1 (shSTAT1) shRNA and total STAT1 and β-actin protein levels were determined by western analysis.  B.  
shNC and shSTAT1 cells were exposed to 5 µM Cr(VI), 200 µM Ni, or Cr(VI) for 2 h prior to adding 200 µM Ni 
for 24 h.  C.  shNC and shSTAT1 cells were exposed to 5 µM Cr(VI) for the indicated times.  D.  Parental BEAS-2B 
cells were pretreated with 10 µg/ml of cycloheximide for 5 min prior to exposure to 5 µM Cr(VI) for the indicated 
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times.  Total RNA was isolated and VEGFA mRNA levels were measured by real-time PCR.  Data represent mean 
± SEM of fold control (n=3).  * and ~ designate p<0.05, *** and ~~~ designate p<0.001 compared to respective 
untreated cells (control); ## and ^^^ designate p<0.01 and p<0.001, respectively, compared to respective cells 
treated with Ni alone. 
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Figure 24.  STAT1 represses HIF-1α protein stabilzation and Sp1 transactivation. 
A.  BEAS-2B cell lines stably expressing either scramble (shNC) or STAT1 (shSTAT1) shRNA were 
exposed to 5 µM Cr(VI), 200 µM Ni, or Cr(VI) for 2 h prior to adding 200 µM Ni for 24 h.  Total protein was 
isolated and HIF-1α and β-actin protein levels were determined by western analysis.    B.  Density of the protein 
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bands from three separate experiments were quantified using ImageJ software and is presented as mean ± SEM of 
fold control (n=3).  *** and ~~~ designate p<0.001 compared to the respective untreated cells (control).  ^^^ 
designates p<0.001 compared to cells treated with Ni alone.  C.  shNC or shSTAT1 cells were transiently 
transfected with Sp1-luc and eGFP and exposed to 5 µM Cr(VI) for the indicated times.  Relative luciferase activity 
of Sp1-luc was normalized to eGFP.  Data represent means ± SEM of fold control (n=3).  ** and *** designate 
p<0.01 and p<0.001, respectively, compared to untreated cells (control). 
4.4 DISCUSSION 
Environmental and occupational exposure to Cr(VI) and Ni cause pulmonary diseases (43,150) 
and although epidemiological studies associate exposure to metal mixtures with exacerbated lung 
injury (37,42,47-49), there are few studies investigating the molecular interaction of these 
metals.  Cr(VI) readily enters airway cells through anion channels where it is rapidly reduced to 
Cr(III) (reviewed in (6)) and exerts effects on both cell signaling processes and DNA.  Exposure 
to Cr(VI) rarely affects the expression of constitutive genes (15,24), but silences inducible gene 
expression in vivo and in vitro (15,19).  While there are substantial amounts of data in the 
literature suggesting that Cr(VI)-induced DNA adducts and ROS generated through the reduction 
of Cr(VI) are responsible for gene silencing (5,16,17,20), there is also ample evidence suggesting 
that Cr(VI) exerts epigenetic effects in silencing gene induction through altering transcriptional 
complexes (19,24).  In the present studies, we examined the effect of Cr(VI) on basal and Ni-
induced signal transduction and VEGFA transcript levels in a pertinent lung target cell using 
concentrations relevant to occupational exposures.  These concentrations are not cytotoxic in this 
cell model ((55) and data not shown), but promote both positive and negative signaling effects 
(19,55).  These studies are the first to identify signaling through STAT1 as an essential 
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regulatory mechanism for Cr(VI)-stimulated gene suppression.  These data may also explain the 
discrepancies observed in other studies where Cr(VI) induced VEGFA in cancer cells whose 
functional STAT1 signaling status is questionable (121) .  
The major stimulus of Ni-induced VEGFA mRNA and protein is HIF-1α stabilization 
(6,118,119).  However, HIF-1α signaling could not be the dominant or sole pathway for Ni-
induced VEGFA in the BEAS-2B cell model, since inhibiting Src completely blocked VEGFA 
mRNA without affecting HIF-1α stability (Figures 19B and 20B).  Although ERK, p38, PI3K, 
and Src have all been implicated as upstream kinases in VEGFA induction in response to a 
variety of stimuli (118,121,123), our data indicates Ni signals through ERK and Src to induce 
VEGFA (Figure 19A-B).  Ni stimulated ERK phosphorylation within 5 min of exposure in 
contrast to Src phosphorylation which required a 30 min exposure to Ni (Fig. 19 and data not 
shown) indicating that ERK is upstream of Src although it is not directly phosphorylating Src.  
The signaling events leading to Src activation from ERK are unclear and beyond the scope of 
this paper.  Furthermore, the upstream dominance of ERK was demonstrated by U0126 
inhibiting both Src phosphorylation (Figure 19C) and HIF-1α stabilization (Figure 20A).  HIF-1α 
cooperates with other transcription factors to transactivate a number of different promoters 
(119,125,156) and the data are consistent with cooperation with Sp1 for full ERK-mediated 
induction of VEGFA (129).  While the data implicate ERK as the primary divergence point for 
the cooperating Ni-stimulated signaling pathways, these studies did not investigate the 
mechanism for Ni-stimulated phosphorylation of ERK or potential interactions of Ni and Cr(VI) 
signaling on upstream kinases.  In addition, Ni activation of ERK may be dependent on cell type 
or cell culture conditions since others fail to observe Ni stimulation of ERK when basal levels 
are high or in transformed airway epithelium (157).   
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Cr(VI) completely blocked both Ni-induced ERK and Src phosphorylation and VEGFA 
mRNA expression (Figs. 18-19).  We previously demonstrated that Cr(VI) had an inhibitory 
effect on both ERK and Src activities (22) and these data suggest that Cr(VI) interferes with their 
activation by Ni to prevent VEGFA induction.  However, Cr(VI) only partially inhibits Ni-
induced HIF-1α protein stabilization (Figure 22A), since Ni-induced HIF-1α stabilization mostly 
results from a direct inhibitory effect on the proline hydroxylases marking the protein for 
ubiquitination and degradation (122).  However, Ni-stimulated activity of the HRE reporter 
construct was completely inhibited by Cr(VI) (Figure 22B).  The HRE reporter construct does 
not contain additional cis elements that might cooperate with HIF-1α binding to the HRE sites.  
Thus, the data are consistent with previous observations that phosphorylation by ERK-mediated 
signaling cascades is required for full transactivation potential of Ni-activated HIF-1α (119).  
Moreover, Cr(VI) had a greater effect on Ni-activated ERK and Src compared to HIF-1α 
indicating that ERK-mediated Src signaling and Sp1 transactivation are more crucial for Ni-
induced VEGFA.  
  STAT1 is a member of the STAT transcription factor family.  Although STAT3 has 
been implicated as an upstream inducer of VEGFA (124), STAT1 is required for IFN-mediated 
inhibition of VEGFA (146).  Cr(VI) activates STAT1 phosphorylation and nuclear translocation 
in parental BEAS-2B cells; although the mechanism of this activation remains uncharacterized 
(55).  The current findings support the hypothesis that STAT1 activation is essential for Cr(VI) 
to repress gene expression.  In addition, they also demonstrate that STAT1 activation blocks the 
Cr(VI) signals that induce VEGFA in shSTAT1 cells or that positively interact with Ni signaling 
(Figure 23B-C).  It is likely that STAT1 suppresses the signaling for activation of factors that 
cooperate with HIF-1α or sequesters these factors by STAT1-induced protein complexes limit 
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Cr(VI) induction of VEGFA in the parental cells.  Recent evidence suggests that IFN-β activated 
a STAT1-containing ISGF3 complex to inhibit Sp1 recruitment or binding of Sp1 and co-
activators (e.g. CBP, p300) to inducible promoters (62,63).  The exact mechanism of this 
inhibition is uncharacterized.  Neither ISGF3 nor any of the individual protein components bind 
directly to the promoters to block transcription, but rather, it is possible that STAT1 stimulates 
an inhibitory protein that interferes with the binding of Sp1.  In the absence of protein synthesis, 
Cr(VI)-induced VEGFA mRNA expression (Figure 23D); suggesting that a protein induced by 
STAT1 transcriptional complexes represses VEGFA induction.  The identity of this protein 
remains unknown, but is being actively investigated.  Since Cr(VI) stimulates Sp1 in the absence 
of STAT1 (Figure 24B) and Sp1 activation is essential for VEGFA expression, it is probably that 
the induced inhibitory protein represses Sp1-dependent transactivation  and induction of the 
VEGFA.  
The antiviral and anti-proliferative effects of IFN-α and IFN-β are limited or reversed to 
proliferative responses in cells that lack STAT1 (152).  STAT1 is deleted in a number of cancers 
(146) and without STAT1 activation, IFN stimulation of STAT3 and 5 or their constitutive 
activation provides a cell survival advantage and can cause transformation (152).  Others 
reported that Cr(VI) stabilizes HIF-1α protein and induces VEGFA in prostate cancer cells (121) 
and we show that Cr(VI) has opposite effects on HIF-1α protein and VEGFA in shNC and 
shSTAT1 cell lines (Figures 23B-C and 24A).  Cr(VI) also has opposite effects on HMOX1 
inducibility in lung cell lines that differ in transformation status (19,158).  Thus, an implication 
of these findings is that, as with IFN responses, Cr(VI) has opposite signaling effects and 
pathogenic actions in normal cells compared to transformed cells that lack functional STAT1.  In 
the normal cells, Cr(VI) would limit inducibility of protective genes or genes involved in injury 
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repair.  In transformed cells, Cr(VI) alone or in combination with other stimuli like Ni might 
promote proliferation and tumor growth by increasing VEGFA or other growth factor 
expression. 
In summary, this study has identified STAT1 activation as an essential and pivotal 
mechanism in Cr(VI)-stimulated gene regulation.  In normal cells exposed to metal mixtures, 
Cr(VI) interferes with Ni-stimulated ERK signaling to compromise the induction of protective 
genes which may exacerbate pulmonary diseases.  Loss of STAT1-mediated transcriptional 
repression unmasks Cr(VI)-stimulated gene induction and enhancement of the Ni response.  
Thus, the data support the conclusion that pathogenic actions of Cr(VI) signaling in lung cells 
and interaction of this signaling with that of other metals in mixtures depend on the STAT1 
status of the airway cells.   
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5.0  NICKEL MOBILIZES INTRACELLULAR ZINC TO INDUCE 
METALLOTHIONEIN IN HUMAN AIRWAY EPITHELIAL CELLS 
The data presented in this chapter is published in 
Am J Respir Cell Mol Biol 2008 Dec 18 [Epub ahead of print]. 
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5.1 ABSTRACT 
We recently reported that induction of MT was critical in limiting Ni-induced lung injury in 
intact mice.  Nonetheless, the mechanism by which Ni induces MT expression is unclear.  We 
hypothesized that the ability of Ni to mobilize Zn may contribute to such regulation and 
therefore, we examined the mechanism for Ni-induced MT2A expression in human airway 
epithelial (BEAS-2B) cells.  Ni induced MT2A transcript levels and protein expression by 4 h.  
Ni also increased the activity of a MRE promoter luciferase reporter construct suggesting that Ni 
induces MRE binding of the MTF-1.  Exposure to Ni resulted in the nuclear translocation of 
MTF-1 and Ni failed to induce MT in MEFs lacking MTF-1.  As Zn is the only metal known to 
directly bind MTF-1, we then showed that Ni increased a labile pool of intracellular Zn in cells 
as revealed by FACS using the Zn-sensitive fluorophore, FluoZin-3.  Ni-induced increases in 
MT2A mRNA and MRE-luciferase activity were sensitive to the Zn chelator, TPEN, supporting 
an important role for Zn in mediating the effect of Ni.  Although neither the source of labile Zn 
nor the mechanism by which Ni liberates labile Zn was apparent, it was noteworthy that Ni 
increased intracellular ROS.  Although both NAC and AA decreased Ni-induced increases in 
ROS, only NAC prevented Ni-induced increases in MT2A mRNA suggesting a special role for 
interactions of Ni, thiols, and Zn release. 
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5.2 INTRODUCTION 
Ni is a well-known environmental and occupational hazard present in air pollution (33), cigarette 
smoke (35), diesel exhaust (36), and welding fumes (37,38).  Ni is a common component of alloy 
metals and is used in electroplating, stainless steel, coins, and jewelry (37,42,159).  Inhalation of 
Ni has been associated with lung and nasal cancers (38,48,160,161), fibrosis, and various other 
cardiopulmonary diseases (33,38), including acute lung injury (37,45). 
MT are highly conserved, small molecular weight, cysteine-rich proteins.  In humans, the 
MT-gene family contains more than 10 members of which MT2A is  most commonly expressed 
(reviewed in (75)).  MT sequesters metals and thus maintains Zn homeostasis and protects cells 
from metal toxicity (76,79,80).  MT also appears to be important in limiting injury due to 
reactive oxygen and nitrogen species (84).  MT transcripts increase during hyperoxic lung injury 
(86), in response to LPS and diesel exhaust particles ((85), and in ovalbumin-induced airway 
inflammation (87).  Furthermore, MT transgenic mice are resistant to Ni- (44) and Cd- induced 
toxicity (75), whereas MT null mice are more susceptible to injury from exposure to Ni (44), Cd 
(75), or LPS (83).  Thus, MT is protective against lung injury (162) and may even serve as a 
therapeutic target in airway diseases (87). 
MT is induced by and capable of binding 18 different metals including Zn and Ni 
(reviewed in (81)), but the precise mechanism of its induction is only known for Zn.  Zn-induced 
MT2A is primarily transcriptionally regulated by Zn causing the MTF-1 to bind multiple copies 
of the MRE in the promoter region (75,90).  The interaction of Zn with MTF-1 is unique since 
this Zn finger protein is directly activated only by Zn relative to other metals (163).  Since MT 
plays an essential role in protecting the lung from Ni-induced injury, we investigated the 
hypothesis that Ni increases MT2A transcript levels in human bronchial airway epithelial cells 
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by mobilizing Zn.  These data support a role for intracellular Zn in the signaling pathway for Ni-
induced increases in MT. 
5.3 RESULTS 
5.3.1 Ni increases MT expression and MRE transactivation 
Exposure to Ni is known to induce MT expression in hepatocytes (79) and in mouse lung (82).  
To examine the effects of Ni on MT2A mRNA levels in airway epithelial cells, BEAS-2B cells 
were exposed to 200 µM Ni (up to 48 h).  Ni increased MT2A transcript levels significantly by 2 
h and remained elevated at 24 h with maximal induction occurring at 4 h after exposure (Figure 
25A).  This induction was time-dependent as determined by linear trend analysis.  Moreover, Ni 
increased MT protein after 4 h as shown by western blotting (Figure 25C).  It is well understood 
that MT expression is regulated at the level of transcription (90).  Although there are numerous 
cis-elements in the promoter region of MT2A, MTF-1 transactivation of MRE is essential for 
both basal and inducible MT expression (90).  Therefore, we tested the hypothesis that Ni 
stimulates the transactivation of MREs to induce MT2A mRNA levels.  pLucMRE luciferase 
activity increased in cells exposed to 200 µM Ni for 4 h or 8 h (Figure 25B).  These data suggest 
that the induction of MT2A by Ni is transcriptionally regulated.  
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Figure 25.  Ni increase MT expression and MRE transactivation 
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A.  BEAS-2B cells were exposed to 200 µM Ni for the indicated times and total RNA was isolated.  MT2A 
mRNA levels were measured by real-time PCR and were normalized to the housekeeping gene RPL13A.  Data 
represent means ± SEM of fold control (n=3).  B.  BEAS-2B cells were transiently transfected with pLucMRE.  
Twenty-four hours after transfection, cells were exposed to 200 µM Ni for the indicated times.  Cells were lysed and 
luciferase assays were performed.  Data represent means ± SEM (n=3).  *, **, and *** designate p<0.05, p<0.01, 
and p<0.001, respectively, compared to untreated cells.  C. BEAS-2B cells were left untreated or exposed to Ni for 4 
h.  Total protein was isolated and western analysis for MT was performed.  The data are representative of duplicate 
samples from 3 separate experiments.  
5.3.2 Nickel stimulates the transactivation of MRE and induces MT2A through a 
Zn-dependent pathway 
Zn increases the binding activity of MTF-1 to induce MT2A (80), but the mechanism for other 
metals, especially Ni, is poorly resolved.  Therefore, we exposed the cells to Ni in the presence 
or absence of TPEN, a Zn chelator, to examine whether Ni activates MREs to induce MT2A 
transcripts by increasing free intracellular Zn.  Cells that were transiently transfected with 
pLucMRE and exposed to TPEN and Ni had decreased luciferase expression compared to cells 
exposed to Ni alone (Figure 26A).  Likewise, the data in Figure 26B show that TPEN 
pretreatment inhibited both Ni and Zn-induced MT2A mRNA levels.  These data indicated that 
the Ni induction of MT2A required free intracellular Zn. 
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Figure 26.  TPEN prevents Ni-induced MRE transactivation and MT2A mRNA expression 
A.  BEAS-2B cells were transiently transfected with pLucMRE.  Twenty-four hours after transfection, cells 
were pretreated with 5 µM TPEN for 30 min prior to exposure to 200 µM Ni for 4 h.  Cells were lysed and 
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luciferase assays were performed.  Data represent means ± SEM (n=3).  B.  BEAS-2B cells were pretreated with 5 
µM TPEN prior to exposure to 200 µM Ni or 100 µM Zn for 2 h.  Total RNA was isolated and MT2A mRNA levels 
were measured by real-time PCR and normalized to the housekeeping gene RPL13A.  Data represent means ± SEM 
of fold control (n=3).  * and *** designate p<0.05 and p<0.001, respectively, compared to untreated cells; ^^^ 
designates p<0.001 compared to cells treated with Ni alone; ~~~ designates p<0.001 compared to cells treated with 
Zn alone. 
5.3.3 Ni activates MTF-1 to induce MT 
To examine the effects of Ni on MTF-1 nuclear localization, we transiently transfected BEAS-
2B cells with eGFP-MTF-1, a reporter molecule with eGFP fused to MTF-1 (139).  After 24 h, 
cells were left untreated or exposed to Ni from 1 h to 4 h.  Exposure to Ni increased MTF-1 
protein in the nucleus (Figure 27A-B).  The requirement of MTF-1 for Ni-induced MT 
expression was also demonstrated using MEFs deficient in MTF-1 (dko7).  Wild-type and dko7 
cells were exposed to Ni for up to 4 h and Mt1 transcript levels were measured.  The data in 
Figure 27C show that in the absence of MTF-1, Ni fails to induce Mt1 transcripts indicating that 
MTF-1 is essential in Ni stimulation of MT. 
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Figure 27.  Ni activates MTF-1 to induce MT expression 
A.  BEAS-2B cells were transiently transfected with eGFP-MTF-1.  Twenty-four hours after transfection, 
cells were replated on chamber slides and exposed to 200 µM Ni for 1 to 4 h or 100 µM Zn for 2 h.  Cells were fixed 
with 4% paraformaldehyde and nuclei were stained with DRAQ5™.  The representative images were captured at 
60X with an Olympus Fluoview 500 confocal microscope.  B.  Quantitative analysis of eGFP-MTF-1 positive nuclei 
is presented as means ± SEM.  * designates p<0.05 compared to untreated cells.  C.  MEF and dko7 cells were 
exposed to 200 µM Ni for the indicated times.  Total RNA was isolated and Mt1 mRNA levels were measured by 
real-time PCR and normalized to the housekeeping gene β-actin.  Data represent means ± SEM of fold control 
(n=3).  ** and *** designate p<0.01 and p<0.001, respectively compared to untreated cells (0 h).  ^^ and ^^^ 
designate  p<0.01 and p<0.001, respectively compared to wild-type MEF cells (WT) at the corresponding time.   
5.3.4 Ni increases ROS, but Ni-induced MT2A expression does not require 
intracellular ROS production 
We previously demonstrated that particulate Ni increases intracellular oxidant production using 
the fluorescent intracellular oxidant indicator CM-H2DCFDA in BEAS-2B cells (119).  The data 
in Figure 28 demonstrated that soluble Ni also increases intracellular ROS in BEAS-2B cells.  
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Increasing the intracellular reduced thiol pool by incubating the cells with 2 mM NAC for 18 h 
or increasing the levels of the antioxidant by incubating the cells with 2 mM ascorbic acid for 30 
min inhibited Ni stimulated ROS production.   However, only treatment with NAC blocked Ni-
induced increases in MT2A transcript levels; suggesting that MT2A is induced by Ni through a 
thiol-dependent, but not ROS-dependent pathway (Figure 29).  
 
 
Figure 28.  Ni-induced intracellular ROS production is prevented by antioxidants 
BEAS-2B cells were pretreated with 2 mM NAC for 18 h or 2 mM L-Ascorbic acid (AA) for 30 min prior 
to loading cells with 20 µM CM-H2DCFDA for 10 min.  Cells were then exposed to 200 µM Ni for 10 min.  
Fluorescence was measured with a fluorescent plate reader with excitation at 485 nm and emission at 530 nm.  Data 
represent means ± SEM (n=3).  *** designates p<0.001 compared to untreated cells; ^^^ and ~~~ designate p<0.001 
compared to cells treated with Ni alone.   
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Figure 29.  NAC, but not AA, prevents Ni-induced MT2A mRNA levels 
BEAS-2B cells were pretreated with A. 2 mM NAC for 18 h or B. 2 mM L-Ascorbic acid (AA) for 30 min 
prior to exposure to 200 µM Ni for 2 h.  Total RNA was isolated and MT2A mRNA levels were measured by real-
time PCR and were normalized to the housekeeping gene RPL13A.  Data represent means ± SEM of fold control 
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(n=3).  ** and *** designate p<0.01 and p<0.001, respectively, compared to untreated cells; ^^^ designates p<0.001 
compared to cells treated with Ni alone. 
5.3.5 Nickel increases intracellular free zinc levels 
To investigate whether Ni signals by increasing free intracellular Zn levels, we performed flow 
cytometry on live cells loaded with the Zn-sensitive fluorophore FluoZin-3.  The data in Figure 
30A demonstrated that exposure to Ni or Zn increased FluoZin-3 fluorescence from 0.2% to 
42.1% and 93.8% of total cells, respectively.  The addition of TPEN attenuated the Ni-induced 
increase in FluoZin-3 (42.1% to 12.0% of total cells) fluorescence suggesting that Ni mobilized 
intracellular Zn.  These experiments used the ionophore, pyrithione, to facilitate the entry of Zn 
and Ni into the cells.  We found that exposure to 20 µM or 200 µM Ni in the presence of 
ionophore mobilized the same amount of labile Zn.  The data in Figure 30B demonstrate that 
exposure to 20 µM Ni in combination with 5 µM pyrithione had a similar induction of MT2A 
mRNA levels after 4 h compared to 200 µM Ni without ionophore.   
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Figure 30.  Ni increases free intracellular zinc 
   
 104 
A.  BEAS-2B cells were loaded with 5 µM FluoZin-3 AM ester with Pluronic F-127.  Cells were exposed 
to 20 µM Ni or 10 µM Zn in the presence of 5 µM pyrithione for 30 min.  TPEN was added for 5 min before 
harvesting to chelate the Zn.  FluoZin-3 fluorescence was measured by flow cytometry.  Data represent the results of 
3 separate experiments.  The percentages on the left and right sides of the histograms represent negative and positive 
Fluozin-3 fluorescence, respectively.  B.  BEAS-2B cells were exposed to 20 µM Ni in combination with 5 µM 
pyrithione or 200 µM Ni alone.  Total RNA was isolated and MT2A mRNA levels were measured by real-time PCR 
and were normalized to the housekeeping gene RPL13A.  Data represent means ± SEM of fold control (n=3).  *** 
designates p<0.001 compared to untreated cells.  
5.4 DISCUSSION 
Ni is a major component of ambient air particulate matter (33,34) that is associated with 
inappropriate immune responses (34,41), airway hyperresponsiveness (42,43), and increased 
cardiopulmonary disease (33).  Mechanisms of action for inhaled Ni that are independent of its 
antigenicity remain poorly defined.  It is evident, however, that without induction of protective 
or adaptive genes, such as increasing MT in airway epithelium, the pathogenic responses to 
inhaled Ni are greatly enhanced (44,82).  These studies used the BEAS-2B cells to model the 
terminal bronchiolar epithelial responses to Ni.  While these cells are SV40 immortalized, we 
have demonstrated that their responses to metals are nearly identical to primary normal human 
bronchiolar epithelial cells cultured on an air/liquid interface (55) and mouse bronchiolar 
epithelium in vivo (19).  Induction of MT following Ni exposure in these cells closely matches 
responses observed in mouse lungs (82) and thus, the mechanisms for this induction in BEAS-2B 
cells are likely to be broadly applicable.  As indicated, MT induction by Ni and other toxic 
metals is a protective response.  However, since only Zn has been shown to directly induce the 
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gene, it remains unclear how Ni and other metals signal for indirect gene activation.  The current 
studies indicate that Ni transcriptionally activates MT2A by first mobilizing intracellular Zn to 
bind with MTF-1.  Ni does not elicit ROS generation to mobilize labile Zn pools, but may 
displace Zn from thiols or interact with regulatory reduced thiols to stimulate MTF-1 
transactivation. 
MT regulates Zn homeostasis and is induced by various stressors including metals 
(76,79,80).  We demonstrated that Ni exacerbated acute lung injury in MT null mice (44) 
acknowledging its protective function in the lung.  MT is basally expressed in the airway 
epithelium (164) and inducible by exogenous chemicals (165,166).  Our data in Figure 25A 
corroborates previous findings that Ni induces MT2A mRNA (79,82).  This induction was rapid 
and time-dependent with the highest expression after 4 h of Ni exposure.  Ni also increased MT 
protein levels after 4 h of Ni exposure (Figure 25C).  There are multiple transcription factors that 
drive MT2A gene expression, but the activation of MTF-1 has an essential role by binding to 
MREs present in the promoter region of MT2A (90).  Ni increased transactivation of MRE 
(Figure 24B), which occurred through the increased binding activity of MTF-1.  Exposure to Ni 
facilitated the translocation of MTF-1 to the nucleus (Figure 27A-B).  Also, Ni did not induce 
MT in cells deficient in MTF-1 (Figure 27C).  However, since only Zn can directly activate and 
increase DNA binding of MTF-1 (90,91), the data support the hypothesis that Ni-induced MT2A 
is caused by redistributed Zn stimulating MTF-1 DNA binding.     
Soluble Ni increased intracellular ROS (Figure 28) which is consistent with our previous 
report using particulate Ni3S2 (119).  Likewise, NAC and AA prevented Ni-increased 
intracellular ROS levels. However, in the previous report, neither antioxidant affected 
transcriptional induction of SERPINE1 following Ni exposures (119).  In contrast, in the current 
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study, only NAC prevented Ni-induced MT2A transcript levels (Figure 29).  Thus, production of 
ROS may not be involved in Ni-induced MT2A, but free thiols may regulate the ability of Ni to 
induce certain genes.  NAC acts as an antioxidant by increasing the intracellular free thiol pool 
and increasing synthesis of glutathione (GSH) (167).  GSH and oxidized gluthothione (GSSG) 
are key regulators of the release of Zn from MT (168,169).  GSSG interacts with MT to facilitate 
the transfer of Zn from MT (169).  However in reducing conditions, when GSH concentrations 
are high, Zn remains bound to MT (168).  The data from Figure 29 suggest that adding NAC 
pushed the thiol balance towards enhanced Zn binding to MT and prevented its mobilization to 
interact with MTF-1.  Exposure to high levels of Ni has been shown to reduce the intracellular 
GSH content and increase the GSSG/GSH ratio (170,171).  Hence it is possible that in our 
system Ni decreased the GSH content of the cell to facilitate Zn mobilization.  However, this is 
unlikely given the low level of oxidant generation in response to Ni and the overwhelming 
amount of intracellular GSH relative to the amount of Ni added.  
Transcriptional activation of MT2A by Ni required Zn mobilization, since pretreatment 
with TPEN, a Zn chelator, abrogated Ni-induced MRE transactivation and increased MT2A 
transcripts (Figure 26).  Although TPEN is often used as a Zn-specific chelator, it has affinities 
for other divalent metals including Ni (76).  However, the stochiometry of TPEN metal chelation 
is such that the low concentration used in the present study was sufficient to bind only 5% of the 
added Ni.  Furthermore, the ability of Zn, but not Ni, to rescue the response observed (Figure 
26B) indicates that the added TPEN predominantly bound the intracellular Zn released by Ni to 
inhibit Ni-stimulated MT induction.  This inhibition did not result from toxicity since TPEN was 
added at a concentration that did not cause cell death (data not shown).  Thus, the observed 
results consistently support a role for mobilization of endogenous Zn in Ni-stimulated signaling.  
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Moreover, increased FluoZin-3 fluorescence after Ni exposure (Figure 30) established that Ni 
increases free intracellular Zn levels as was previously demonstrated in hepatocytes (172).  In 
summary, we demonstrated that Ni increases free intracellular Zn levels to induce MT2A 
transcript levels.  This was not at the level of MT itself, since Ni has a low affinity for MT, 
relative to Zn, and cannot displace Zn from MT (76).  The precise mechanism of how Ni is 
redistributing Zn has not been investigated fully, but remains an area of interest.  However, this 
study elucidates the mechanism of Ni-induced MT2A and provides a better understanding of 
how metals other than Zn produce this adaptive response.  This understanding may offer insight 
for developing protective strategies to reduce pathogenic airway responses to inhaled metals. 
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6.0  CONCLUSIONS 
6.1 CHROMIUM AND PULMONARY DISEASE 
Chronic exposure to Cr(VI) causes lung diseases including asthma, chronic bronchitis, airway 
hypersensitivities, and lung cancer (13).  These diseases occur more frequently in workers in the 
industries where levels of Cr(VI) are highest.  The data presented in this dissertation proposes a 
possible mechanism that may explain the association between inhalation of Cr(VI) with 
pulmonary diseases.  This mechanism involves the selective activation of the SFK, Fyn, leading 
to the stimulation of STAT1 and the repression of the protective genes, MT and VEGFA, 
induced by Ni in the lung.  Studies using mice deficient in STAT1 are required to verify that this 
pathway is involved in the pathogenesis of Cr(VI)-induced pulmonary diseases.  The 
confirmation of this pathway will provide insight into how to better protect people from these 
diseases.   
6.2 METAL MIXTURES 
Epidemiological studies associate exposure to metal mixtures with increased incidence of 
pulmonary diseases.  Despite this association, few studies have examined how metals may 
interact to promote diseases.  In this dissertation, cell signaling mechanisms of Cr(VI) and Ni 
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were examined both separately and in combination.  These two metals were studied because they 
are often found together in industry, are present in over half of the NPL toxic waste sites, and 
have been shown to positively interact in causing lung disease (42,46-49).  The data in Chapters 
4 and 5 demonstrated that following exposure to Ni, MT and VEGFA were induced in BEAS-2B 
cells.  However, in cells pretreated with Cr(VI), this induction was inhibited (Figures 18 and 32) 
which was mediated by the activation of STAT1 signaling.  These data suggest that exposure to 
metal mixtures results in a worsened outcome compared to exposure to either one individually.  
Further studies are needed to verify that exposure to both metals result in exacerbated lung 
diseases compared to the individual metal. 
6.3 MECHANISM OF CR(VI)-ACTIVATED STAT1 SIGNALING 
STAT1 plays an important role in the innate immune response and promotes antiproliferative 
and antiviral effects (67,68).  STAT1 is specifically activated in the bronchial epithelial cells of 
asthmatic patients and its aberrant expression may be vital to the development of inflammatory 
pulmonary diseases (1).  The ability of Cr(VI) to activate STAT1 was demonstrated in Chapter 3.  
In BEAS-2B cells, Cr(VI) stimulated STAT1 phosphorylation leading to the dimerization with 
STAT2, transactivation of ISRE, and the induction of IRF7 mRNA.  The STAT1-STAT2 dimer 
binds IRF9 to form the ISGF3 complex.  This complex is of biological relevance because studies 
have shown that ISGF3 activation silences IFNβ-induced genes (62,63).  Although the precise 
mechanism of this repression is unknown, all three protein components are needed.  Surprisingly, 
the proteins do not bind directly to the promoters of these genes, but instead may activate an 
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inhibitory protein that either sequesters the necessary transcription factors in the nucleus, or 
binds to the promoter and blocks its binding (62,63).   
Histone modifications are an important method for gene regulation.  Typically, histone 
deacetylation is associated with gene repression and acetylation with gene activation (173).  
However, in unique cases, histone deacetylation is required for gene induction.  Specifically, this 
modification is needed for activation of ISRE-driven genes, but not GAS-driven genes (60,61).  
HDAC is required for the recruitment of transcriptional machinery to the promoters of these 
genes (61).  Cr(VI) has been shown to prevent the liberation of HDAC from the promoters of 
PAH-inducible genes resulting in the prevention of RNA polymerase II recruitment and the 
silencing of the gene induction (24).  It was demonstrated in Figure 13 that Cr(VI) induction of 
IRF7 mRNA required HDAC activity since pretreatment with the HDAC inhibitor, NaB, 
prevented the induction.  However, NaB pretreatment had no effect on Ni-induced VEGFA 
mRNA expression (Figure 37) indicating that Cr(VI) is not silencing this gene through a HDAC-
dependent mechanism.   
STAT1 was initially discovered as a downstream effector of IFN signaling (52).  
Although treatment with an IFNAR neutralizing antibody prevented IFN-induced IRF7 mRNA 
expression, it had no effect on Cr(VI)-induced IRF7 suggesting that Cr(VI) activates STAT1 
through an IFN-independent mechanism.  Furthermore, preincubating cells with IFN-α2 prior to 
Ni exposure had no effect on MT2A or VEGF mRNA expression (Figures 35-36).  These data 
indicate that while STAT1 is required for Cr(VI) repression of Ni-induced genes, it is not 
through the stimulation of IFN.  These data further indicate that STAT1 is indirectly affecting 
gene induction through the induction of an inhibitory protein.     
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It has been previously shown that Cr(VI) directly activates affinity purified Fyn in vitro 
(22).  There are critical cysteine residues in regulatory domain of Fyn that regulates substrate 
phosphorylation (174).  This domain is highly conserved among SFKs with the two cysteines 
flanking eleven amino acids.  These cysteines are targets of oxidant (174) and metal 
(74,175,176) effects on substrate recognition.  However, it is not known whether Cr(VI) can 
directly bind this motif to activate Fyn.  Although Fyn is the initial target of Cr(VI) signaling, it 
might not be directly phosphorylating STAT1.  c-Abl is a NRTK that is ubiquitously expressed 
and activated by various factors including SFKs (177).  Specifically, Src and Fyn phosphorylate 
c-Abl and increase its kinase activity (147).  Gleevec, a specific inhibitor of c-Abl, can be used to 
examine the requirement of c-Abl for Fyn-mediated activation of STAT1.  Csk is a soluble PTK 
that regulates SFKs by phosphorylating an inhibitory tyrosine residue in the C-terminus (178).  
Mg ions are required for this reaction and other metal ions (Mn, Co, Ni, Zn) are capable of 
binding to the Mg binding site and altering the activity of Csk (175).  Currently there is no 
evidence that Cr(VI) can bind this site or if it can compete with Mg ions, but it remains a 
possibility of how Cr(VI) may activate STAT1 signaling.   
Cr(VI) is well known for its negative effect on the gene inducibility.  The overall hypothesis of 
this dissertation is that Cr(VI)-activated STAT1 signaling is responsible for the repression of genes and 
the data presented supports the idea that STAT1 acts as a master regulator of Cr(VI)-induced gene 
regulation.  The data in Chapter 4 and Appendix A demonstrated that in STAT1-deficient cells, Cr(VI) 
induced VEGFA and MT2A.  Moreover, Cr(VI) positively interacted with Ni signaling to further increase 
the transcription of these genes.  Functional STAT1 is often lacking in cancers (146), which can 
explain the differential effects of Cr(VI) on expression of the same gene in different cell lines.  
Contrary to the data in Chapter 4, Cr(VI) stabilized HIF-1α and induced VEGFA mRNA in 
prostate cancer cells (121) and also had opposite effects on HO-1 mRNA expression in normal 
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cell lines compared to cancerous cell lines (19,158).  Therefore, the pathogenic actions of Cr(VI) 
signaling in lung cells and interactions with other metals may depend on the STAT1 status of the 
airway cells.  
6.4 TRANSCRIPTIONAL REGULATION OF VEGFA BY CHROMIUM AND 
NICKEL 
VEGFA is most known for its role in angiogenesis and vascularization.  Although its role in the 
lung and the airway epithelial cells remains controversial and largely unknown, VEGFA is an 
important mediator of wound healing and repair (113,115).  In cancers, hypoxic conditions 
stabilize HIF-1α to induce VEGFA expression and although hypoxia is the main inducer of HIF-
1α, metals, including Ni, can also stabilize HIF-1α (118,119,122,141).  The exact mechanism of 
this stabilization is unknown, but it is hypothesized that Ni may interfere with the proteins 
involved in the degradation or the transcriptional activation of HIF-1α (e.g. prolyl hydroxylase 
domain (PHD), asparagine hydroxylases, respectively).  PHDs hydroxylate HIF-1α prolines to 
promote binding to the VHL ubiquination complex allowing it to be degraded.  Ni decreases the 
binding of VHL to HIF-1α and that stabilization of HIF-1α was a persistent response indicated 
by its presence for up to 72 h after Ni was removed from the media of cells in culture (122).  
However, the function of HIF-1α was not examined in these studies.  The PHD enzymes require 
iron, ascorbic acid, and oxygen for proper function (179).  Previous studies from our laboratory 
showed that preincubation of cells with antioxidants had no effect on Ni-induced HIF-1α 
stabilization or transactivation suggesting that Ni stabilization of HIF-1α may be due to Ni 
displacing iron from the PHDs rendering them inactive (119).  In addition to the PHDs, 
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hydroxylation of an asparagine residue in the C-terminal transactivation domain is required for 
the interaction of HIF-1α with co-activators (e.g. p300).  In vitro assays using purified HIF-1α 
fragments showed that the hydroxylation of asparagine is directly inhibited by metals (e.g. Co 
and Zn) (180) thereby suggesting that this may be a mechanism of Ni-induced HIF-1α 
stabilization.     
There is growing evidence that upstream kinases are involved in mediating HIF-1α 
phosphorylation and transactivation.  In the studies in Chapter 4, it was demonstrated that Ni-
activated ERK was partially responsible for HIF-1α stabilization knocking it down by 54% 
(Figure 20A).  The partial inhibition could result from either the activation of other upstream 
kinases not examined or more likely, through altering the degradation pathway by interfering 
with PHDs or inhibiting asparagine hydroxylases activity.  However, it is important to note that 
not all of HIF-1α protein that is stabilized by Ni is functional.  Ni robustly increases HIF-1α 
protein stabilization (Figure 22A), but the transactivation of HRE was increased only about 2 
fold in response to Ni (Figure 22B).  Although this observation could be due to the lack of 
sensitivity of the HRE luciferase assay, it strongly suggests that while Ni may increase the 
stability of the protein, it is not transcriptionally active.  Further analysis of the phosphorylation 
status and nuclear localization of HIF-1α is required to address this hypothesis.   
As stated above, there is evidence of kinase involvement in the induction of VEGFA.  
Specifically in cancer cells and tumors, Src and STAT3 appear to be essential mediators of 
VEGFA expression (124).  In other systems, different kinases including MAPKs and PI3K are 
involved in the signaling pathway (118,119).  The precise signaling is dependent on the cell type 
and stimuli.  In BEAS-2B cells exposed to Ni, ERK was activated and was upstream of HIF-1α 
transactivation and Src-mediated Sp1 transactivation (Figures 19C, 20A, and 31).  p38 and PI3K 
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had no role in either the induction of VEGFA or HIF-1α stabilization (Figures 19A and 20A).  
ERK activation was determined to be upstream of Src, since inhibiting ERK prevented Ni-
stimulated Src phosphorylation (Figure 19C).  Inhibiting Src prevented Ni-induced VEGFA 
mRNA expression without affecting HIF-1α stabilization (Figures 19B and 20B) indicating that 
both HIF-1α dependent and independent signaling is required for VEGFA induction.  However, 
the mechanism by which Ni activates ERK remains unknown.  Ni may be activating MEK1/2 to 
phosphorylate ERK, and this activation could be direct or mediated through receptors (e.g. 
GPCRs).   
Sp1 phophorylation is required for full induction of VEGFA (129).  Although Sp1 
phosphorylation status was not examined, Ni stimulated increased binding to Sp1 as shown by 
luciferase assays.  It is likely that the phosphorylation is mediated by ERK and Src, but other 
kinases have also been implicated in the activation of Sp1 (e.g. DNA-PK, CDKs, PI-3K).  Sp1 
can be phosphorylated on 5 different Ser/Thr residues with the biological response being 
dependent on the specific site.  ERK-mediated Sp1 activation of VEGFA is dependent on the 
phosphorylation of Thr453 and Thr739 (131).  Due to the lack of available antibodies specific to 
each phosphorylation site, site-directed mutagenesis will need to be employed to determine 
which residue(s) is important for Ni-induced VEGFA expression.  To determine the requirement 
of ERK and Src, electrophoretic mobility shift assays for Sp1 DNA binding can be performed 
after preincubation of cells with the specific inhibitors to each kinase prior to Ni exposure.   
When Cr(VI) was added to the cells prior to Ni exposure, Ni-activation of ERK, Src, 
HIF-1α, and VEGFA was inhibited (Figures 21-22).  The effect of Cr(VI) on HIF-1α 
stabilization was only partial, but completely blocked HRE transactivation (Figure 22) once 
again suggesting that not all of the protein stabilized by Ni is functional.  Cr(VI) is known to 
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prevent the recruitment of co-activators to promoters (26) so it is possible Cr(VI) may be 
repressing HIF-1α transactivation through interfering with the asparagine hydroxylase and needs 
to be investigated further.  Also, the mechanism of the inhibitory effect of Cr(VI) on ERK 
remains unknown.  Previous reports demonstrated that Cr(VI) decreases basal ERK 
phosphorylation (22) but whether this effect is direct or through altering the upstream signaling 
events needs to be studies.   
STAT1 signaling is required for Cr(VI) effects on VEGFA repression.  In shSTAT1 cells, 
Cr(VI) induced VEGFA mRNA levels (Figure 23C) and further increased the Ni response 
(Figure 23B).  HIF-1α cooperates with other transcription factors and it is probable that STAT1 
or the STAT1-containing complex sequesters these transcription factors or prevents them from 
binding the VEGFA promoter through the induction of an inhibitory protein.  In the absence of 
protein synthesis, Cr(VI) induces VEGFA mRNA expression (Figure 23D) in the same time 
frame as in shSTAT1 cells (Figure 23C) suggesting that a protein activated by STAT1 
transcriptional complexes repress VEGFA induction.  The identification of this inhibitory protein 
is vital to understanding the development of Cr(VI)-induced pulmonary diseases.  Since Cr(VI) 
activates STAT1 (55) and induces VEGFA in the absence of STAT1 (Figure 23C) and protein 
synthesis (Figure 23D) within one hour, this inhibitroy protein must be present within 1 h of 
Cr(VI) treatment.  Also, the ISGF3 complex interferes with Sp1 recruitment to inducible 
promoters (62) and Cr(VI) stimulates Sp1 transactivation in the absence of STAT1 (Figure 24B).  
Therefore it is possible that the inhibitory protein is interacting with Sp1 and preventing its 
transactivation.  One approach to identifying this protein is to immunoprecipitate Sp1 from 
whole cell lysate after Cr(VI) exposure.  The immunoprecipitate can be separated by SDS-PAGE 
and the proteins can be identified by mass spectrometry.  Also, the shNC and shSTAT1 cells can 
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be exposed to Cr(VI) and proteins separated by SDS-PAGE.  Proteins present in the shNC cells, 
but not in the shSTAT1 cells will be identified by mass spectrometry.     
6.5 TRANSCRIPTIONAL REGULATION OF MT2A BY CHROMIUM AND NICKEL 
MT is well known for its role in metal detoxification and protection against environmental 
insults.  It has been demonstrated that exposure to Ni rapidly induced MT expression and is 
crucial in protecting against Ni-induced lung injury (44).  However, only the mechanism for Zn-
induced MT is known.  The data in Chapter 5 demonstrated that exposure to Ni caused the 
redistribution of Zn which directly activated MTF-1 to transcribe MT2A, the major human 
isoform of MT.  The precise mechanism for how Ni mobilizes Zn remains unknown since Ni 
cannot displace Zn from MT or other Zn-binding proteins (76).  Ni increases in labile Zn did not 
arise from the production of ROS.  Exposure to Ni modestly increased intracellular ROS 
production (Figure 28), but preincubation with ascorbic acid had no effect on Ni-induced MT2A 
(Figure 29B).  In contrast, increasing intracellular free thiols through the addition of NAC 
prevented Ni-induced MT2A mRNA expression (Figure 29A).  NAC is a precursor to GSH and 
when GSH concentrations are high, Zn remains tightly bound to MT (168).  Although Ni can 
decrease the GSH content of cells, it requires higher concentrations of Ni than used in these 
studies (170,171).  Thus, the mechanism of Ni mobilized Zn requires further examination.   
MT2A is primarily transcriptionally regulated through the binding of MTF-1 to MREs in 
the MT2A promoter (90).  Ni increased MT mRNA, protein, and MRE transactivation (Figure 
25).  Exposure to Ni activated MTF-1 nuclear localization and Ni did not induce MT transcripts 
in MTF-1-null cells (Figure 27).  Zn directly activated MTF-1 and TPEN treatment prevented 
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MT2A induction indicating the requirement of Zn for this response (Figure 26).  Furthermore, 
exposure to Ni caused an increase in a Zn-specific fluorophore (Figure 30).  In addition to Zn-
dependent mechanisms for the activation of MTF-1, its phosphorylation is also critical for its 
activity (90-92).  Ni activation of p38, PI-3K, and SFKs were determined to be necessary for the 
prolonged induction of MT2A mRNA which was demonstrated by the loss of Ni-induced MT2A 
transcripts in the presence of the specific inhibitors (Figure 33).  
Cr(VI) has been shown to inhibit Zn- and Cd-induced MT expression by interfering with 
the transactivation potential of MTF-1 (23) and preventing RNA polymerase II recruitment to the 
promoter (25).  Cr(VI) has no effect on Ni-induced MT2A transcripts until after 8 h of exposure 
(Figure 32) suggesting that Cr(VI) has no effect on the redistribution of Zn, but may affect the 
upstream kinases activated by Ni.  Interestingly, in cells deficient in STAT1, Cr(VI) modestly 
induces MT2A mRNA expression and greatly increases MT2A in the presence of Ni (Figure 34).  
It remains unknown how Cr(VI)-activated STAT1 may interfere with MT2A induction, but MTF-
1 also cooperates with other transcription factors including HIF-1α and Sp1 (93-96) and Cr(VI) 
interferes with their transactivation (Figures 22B and 24B). 
6.6 SUMMARY 
In conclusion, these studies demonstrated that exposure to occupationally relevant concentrations 
of Cr(VI) activates STAT1-dependent signaling to alter the transactivation of basal and Ni-
induced protective genes in airway epithelial cells (Figure 31).  Cr(VI) directly activates the 
SFK, Fyn, to initiate this signaling cascade.  More importantly, the stimulation of STAT1 
phosphorylation appears to be the determining factor of Cr(VI) effects on VEGFA and MT2A 
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induction.  The exact mechanism of Cr(VI) repression is unresolved.  However, these studies 
provide evidence that STAT1 is crucial in the regulation of genes by Cr(VI).  Definitive 
experiments can be designed that will provide support for the hypothesis that Cr(VI)-activated 
STAT1 is an essential mediator of Cr(VI)-induced pulmonary diseases. 
Future directions of this work include investigating the effects of Cr(VI) and Ni exposure 
both acutely and chronically in vivo, identifying the mechanism by which Cr(VI) activates Fyn, 
and investigating how STAT1 disrupts the transcriptional complexes required to drive inducible 
gene expression.  The mechanism revealed by this research is necessary for understanding the 
toxic effects of inhaled metals and metal mixtures and for improving the prevention and 
treatment of metal-induced pulmonary diseases.   
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Figure 31.  Proposed signaling scheme for the role of STAT1 in Cr(VI) signaling for repressed gene 
induction. 
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APPENDIX A  
                  SUPPLEMENTAL FIGURES
 
THE EFFECT OF CR(VI) ON NI-INDUCED MT2A 
 
Figure 32.  Cr(VI) effects on Ni-induced MT2A mRNA levels. 
BEAS-2B cells were exposed to 5µM Cr(VI), 200 µM Ni, Cr(VI) for 30 min prior to 200 µM Ni for the 
indicated times.  Total RNA was isolated.  MT2A mRNA levels were measured by real-time PCR and normalized to 
the housekeeping gene, RPL13A.  Data represent mean ± SEM of fold control.  *** designates p<0.001 compared to 
respective control; ^^^ designates p<0.001 compared to Ni alone. 
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THE EFFECT OF KINASE INHIBITORS ON NI-INDUCED MT2A 
 
Figure 33.  The role of kinase signaling in Ni-induced MT2A mRNA levels. 
BEAS-2B cells were pretreated with 10 µM U0126, 20 µM SB203580, 1 µM wortmannin, or 10 µM PP2 
prior to adding vehicle (open bars) or 200 µM Ni (closed bars) for 24 h.  Total RNA was isolated.  MT2A mRNA 
levels were measured by real-time PCR and normalized to the housekeeping gene RPL13A.  Data represent mean ± 
SEM.  *** designates p<0.001 compared to respective control; ^^^ designates p<0.001 compared to Ni alone.   
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STAT1 IS REQUIRED FOR CR(VI) SILENCING OF NI-INDUCED MT2A 
 
Figure 34.  STAT1 is required for Cr(VI) suppression of MT2A induction. 
BEAS-2B cells stably expressing either random (shNC) or STAT1 (shSTAT1) shRNA  were exposed to 5 
µM Cr(VI), 200 µM Ni, or 5 µM Cr(VI) for 2 h prior to the addition of 200 µM Ni for 24 h.  Total RNA was 
isolated.  MT2A mRNA levels were measured by real-time PCR.  Data represent mean ± SEM of fold control.  *** 
deginates p<0.001; ~~ and ~~~ designate p<0.01 and 0.001 compared to respective control cells.  ^^ designates 
p<0.01 compared to cells treated with Ni alone. 
   
 123 
 
THE EFFECT OF IFN-Α2 ON NI-INDUCED MT2A 
 
 
 
Figure 35.  IFN-α2 has no effect on Ni-induced MT2A mRNA levels. 
BEAS-2B cells were preincubated with 100 U/ml IFN-α2 for 2 h prior to exposure to vehicle (open bars) or 
200 µM Ni (closed bars) for 24h.  Total RNA was isolated and MT2A mRNA levels were measured by real-time 
PCR.  Data represent mean ± SEM of fold control.  *** designates p<0.001 compared to the respective control. 
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THE EFFECT OF IFN-A2 ON NI-INDUCED VEGFA 
 
Figure 36.  IFN-α2 has no effect on Ni-induced VEGFA mRNA levels. 
BEAS-2B cells were preincubated with 100 U/ml IFN-α2 for 2 h prior to exposure to vehicle (open bars) or 
200 µM Ni (closed bars) for 24h.  Total RNA was isolated and VEGFA mRNA levels were measured by real-time 
PCR.  Data represent mean ± SEM of fold control.  ** and *** designate p<0.01 and 0.001, respectively, compared 
to the  respective control. 
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THE EFFECT OF HDAC ON NI-INDUCED VEGFA 
 
Figure 37.  HDAC activity is not required for repression of Ni-induced VEGFA mRNA expression. 
BEAS-2B cells were preincubated with 2 mM NaB for 16 h prior to exposure to vehicle (open bars) or 200 
µM Ni (closed bars) for 24h.  Total RNA was isolated and VEGFA mRNA levels were measured by real-time PCR.  
Data represent mean ± SEM of fold control.  ** designates p<0.01 compared to the respective control. 
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